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ABSTRACT 
 
Autism spectrum disorders (ASD) comprise a genetically heterogeneous group of 
neurodevelopmental disabilities characterized by repetitive behaviors as well as deficits in 
communication and social/emotional interactions and behaviors.  
Defects in GABA transmission have been hypothesized to underlie the symptoms of ASD 
(Ben-Ari, Khalilov, Kahle, & Cherubini, 2012). Engrailed-2 (En2) is a homeodomain 
transcription factor involved in regionalization and patterning of the midbrain and hindbrain 
regions (Joyner, 1996; Gherbassi and Simon, 2006). En2 is expressed in the developing 
and adult mouse midbrain/hindbrain region (Joyner, 1996), as well as the adult mouse 
forebrain (Tripathi et al., 2009). Genome wide association studies have shown that two 
intronic single-nucleotide polymorphisms in the human En2 gene are significantly 
associated with ASD (Benayed et al., 2009). En2-/- mice lack the homeodomain of En2 
(En2hd/hd mice; Joyner et al., 1991, referred to as En2-/-) and display neuropathological 
and behavioral changes relevant to ASD. We first investigated the distribution of different 
interneuron subtypes in the cerebral cortex and hippocampus of En2-/- mice. Results 
showed a significant loss of parvalbumin, somatostatin and neuropetide Y positive 
interneurons, in both regions of En2-/- brains. 
Brain-derived neurotrophic factor (BDNF) is a crucial factor for the postnatal development 
of forebrain GABAergic neurons, namely PV interneurons. We therefore investigated 
whether altered BDNF expression may be related to the altered development of 
GABAergic interneurons, described in En2-/- mice. Considering the important role of BDNF 
in forebrain GABAergic interneuron development, we decided to determine whether 
interneuron loss in En2-/- forebrain might be related to altered expression of BDNF and its 
signaling receptors. We evaluated the expression of different BDNF mRNA and protein 
isoforms in various brain areas from wild-type (WT) and En2-/- mice. Quantitative RT-PCR 
indicated an alteration of various splicing variants of BDNF mRNA in the cerebral cortex 
but not hippocampus and cerebellum of adult En2-/- mice, as compared to WT controls. 
Immunoblot analyses instead revealed increased levels of mature BDNF and reduced 
levels of truncated- and pro-BDNF isoforms in the hippocampus of En2-/- vs. WT mice. 
These data indicate a role of BDNF in the anatomical phenotype of En2-/- mice, 
suggesting that BDNF might be involved in the developmental defects of the GABAergic 
system in this mouse model of ASD. We next investigated the effect of BDNF on 
GABAergic and glutamatergic neuron connectivity using primary cultures of hippocampal 
neurons from WT and En2-/- mice. Results showed that BDNF is able to increase the 
number of GABAergic and glutamatergic synaptic contacts in En2-/- hippocampal neurons. 
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Taken together, our results suggest a beneficial role of BDNF in rescuing synaptic defects 
in En2-/- mice 
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LIST OF ABBREVIATIONS 
 
AIS:  Axon initial segment  
ASD: Autism Spectrum Disorder 
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GAT: GABA transporter 
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1. INTRODUCTION 
1.1 Autism spectrum disorders  
Autism spectrum disorders (ASD) comprise a highly heterogeneous set of related 
neurodevelopmental disorders classified as part of Pervasive Developmental Disorders 
(PDDs) in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, published 
in 2013.  In addition to autism, in DSM-V, have been included disorders that were 
previously diagnosed separately, such as autistic disorder, Asperger‘s disorder, childhood 
disintegrative disorder, and pervasive developmental disorder not otherwise specified.  
ASD are characterized by some common aspects, such as impairment in reciprocal social 
interaction, marked deficits in verbal and nonverbal communication, restricted, repetitive 
and stereotyped interests and behaviors (DiCicco-Bloom et al., 2006). Autistic symptoms 
are typically noticed in the first or second year of life: clinical diagnosis is made at about 
two years of age, because of the necessity to assess motor and communication skills of 
the children. By the age of three, deficits characterizing ASD are generally recognizable 
(Miles, 2011). Manifestations of these disorders consist in delay or abnormality in language 
and play, repetitive behaviors, unusual interest.  
Recent studies demonstrated that ASD are much more common than previously believed 
(Payakachat et al., 2012). Before 1982, the estimated prevalence of autism was 4.5 per 
10.000 according to Kanner‘s criteria (Lotter, 1966) (Fombonne, 1999); subsequently,  
DSM-IV studies found proportions of autistic disorder at 15 to 40 per 10.000 (Wing & 
Potter, 2002). Other studies revealed a prevalence of 70 to 113 per 10.000, or about 1% of 
the population (Fombonne et al., 2009). In 2013, Blumberg and colleagues showed parent-
reported rates of 2% of children (Blumberg et al., 2013). The mode of inheritance seems to 
be complex and boys being affected more frequently than girls (Crawley et al., 
2004)(Llaneza et al., 2010). ASD appear to be a syndrome of complex genetic traits and 
during pregnancy different exposures to allergenic environmental factors, autoimmune 
problems, viral infections, maternal anticonvulsants (valproic acid) may be implicated in the 
etiology of ASD (London, 2000) (Trottier at al.,1999)(Arndt, et al., 2004). Even premature 
birth has been implicated as a cause of ASD, therefore, it has been demonstrated that 
babies from gestations of less than 28 weeks have a high risk of neurological problems 
(Agnes Cristina Fett-Conteal et al., 2013). Etiology is not well known and in a minority of 
cases (less than 10%) autism is part of another condition: cases include tuberous 
sclerosis, Fragile X syndrome (FXS), phenylketonuria and congenital infections secondary 
to rubella and cytomegalovirus (Faras, et al., 2010). 
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ASD is diagnosed when the characteristics deficits of social communications are 
complemented to repetitive behavior and restricted interests: it has been well-defined that 
genetic conditions could give rise to distinct patterns of autistic disease (Bruining et al., 
2014). Patterns of autistic symptomatology can be associated with specific genetic 
disorders: different studies have indicated that a specific disorder referred to specific 
behavioral phenotype (Hall et al.,2010)(Pride et al.,2012) (Bruining et al., 2014). Several 
well-described single-gene disorders have been reported in ASD, as a part of the 
expanded phenotype associated with changes in that gene (Agnes Cristina Fett-Conte, 
2013).  
Different genetic diseases are associated with ASD, such as Rett syndrome, Asperger 
Syndrome, tuberous sclerosis and Fragile X syndrome. Sakai and colleagues evaluated 
the association of identified genes with ASD and recognized the molecular clusters 
associated with this syndrome (Neale et al., 2012). They discovered that two autism 
associated protein, SHANK and NLG3, may interact with protein associated to ASD (Sakai 
et al., 2011)(Baudouin, 2014). ASD is a constellation of monogenic disorders that 
converge to a narrower set of behavioral symptoms (Baudouin, 2014). The regulation of 
clusters of genes involved in the cortical development has been studied by Voineagu and 
colleagues, which discovered a difference in the gene expression in ASD patients 
(Voineagu et al., 2011). They identified a group of genes correlated with synaptic function 
and neuronal signaling involved in development (Baudouin, 2014). About 500 genes have 
been associated with diverse forms of ASD, each of them have been reported in a small 
fraction of the cases of ASD (Baudouin, 2014)(Gilman et al., 2011).  
1.1.1 Genetics of autism 
Autism is a common and heritable neuropsychiatric disorder that can be divided into two 
types of pathology: syndromic autism (associated with a known genetic syndrome) and 
non-syndromic autism (Miles et al., 2011) (Singh & Eroglu, 2013), which comprises a vast 
majority of autism cases (Geschwind et al., 2011).  About 10%-20% of individuals with an 
ASD have an identified genetic etiology. Chromosomal alterations have been reported in 
∼5% of cases copy number variants (CNVs) and single-gene disorders (~5%)(Gilman et 
al., 2011)(Muhle et al., 2004)(Neale et al., 2012). Syndromic ASD genes are defined as 
those genes predisposing to autism in the context of a syndromic disorder. The distinction 
between syndromic and non-syndromic terminology is not precise, and several genes, 
initially identified in syndromic conditions, were later reported in subjects with non-
syndromic forms (Betancurlet et al., 2011) (Betancur et al., 2009). Monogenic disorders 
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described in ASD include Neurofibromatosis (NF1), Angelman syndrome (UBE3A), 
SHANK3 alteration, Rett Syndrome (MECP2) and PTEN mutations in patients with 
macrocephaly and autism ( Berkel et al., 2010)(Durand et al., 2007) (Geschwind & Levitt, 
2007) (Hatton et al., 2006) (Veenstra-Vanderweele et al., 2004). In addition, genome wide 
association studies revealed mutations in DLX, Reelin and Engrailed genes, resulting in 
autism phenotypes and neuropathology (Gadad et al., 2013). Disorders known for their 
high comorbidity with ASD include Fragile X syndrome (FMR1), the most common single 
gene mutation account to autism, present in ∼ 2% of cases (Betancur et al., 2011). 
Rare mutations have been identified in synaptic genes, including NLGN3 and NLGN4X 
(Jamain et al., 2003): Neurexins and Neuroligins are synaptic cell-adhesion molecules that 
connect pre- and postsynaptic neurons at synapses (Laumonnier et al., 2004). Four 
Neuroligin isoforms have been identified in mice and five in humans (Südhof, 2008). Series 
of mutations have been found in NLGN1, 3 and 4 genes in patients with familial ASD, 
which primarily lead to a decrease or an absence of protein expression (Jamain et al., 
2003) (Südhof et al., 2008). Non-syndromic disease is not correlated to other neurological 
syndromes and is heritable: loss-of-function and gain-of-function mutations in 
NLGN3 and NLGN4 genes are linked to class of autism (Betancur, 2011) (Singh et al., 
2013). In line with this, only NLGN3 and NLGN4 mouse models present autism-related 
behavioral phenotypes (Tabuchi et al., 2007).  
 
Another important disorder recognized to have an increased risk in autistic population is 
neurofibromatosis (Gillberg & Forsell, 1984)(Caglayan, 2010): 5%–10% of patients with 
neurofibromatosis 1 (NF1) have a 17q11 deletion involving NF1 and other genes 
(Betancur, 2011) (Tonsgard et al.,1997). The NF1 gene encodes for a protein called 
neurofibromin, a GTPase activator involved in the regulation of the Ras/ERK signaling 
(Martin et al., 1990). The NF1 microdeletion syndrome is characterized by a more severe 
phenotype than that observed in patients with intragenic NF1 mutations (Caglayan et al., 
2010).  
 
Autism is considered part of the behavioral phenotype found in Angelman syndrome (AS) 
(Bonati et al., 2007). This syndrome presents genetic alterations, in detail: deletion on the 
maternal chromosome 15 (70%), paternal chromosome 15 uniparental disomy (UPD; 2%) 
point mutations of the UBE3A gene (10%) and epimutations. No identifiable molecular 
abnormality is found in the remaining AS patients (10–13%) (Bonati et al., 2007). The most 
common chromosomal rearrangement is the maternal duplication of 15q11-q13, which 
accounts for approximately 1-2% of ASD cases (Bonati et al., 2007) (Kishino et al., 1997). 
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ASD or autistic features are associated with a wide mutation spectrum, that includes  
missense, frameshift, nonsense, and intragenic deletions (Moretti et al., 2006). For 
example, MECP2 mutations or deletions cause Rett syndrome in females, and congenital 
encephalopathy (Herman et al., 2007). The MECP2 gene is located in Xq28 and is subject 
to X-chromosome inactivation (Young et al., 2004).  It is a member of a family of proteins 
that bind regions of DNA enriched with methylated CpG regions; human MECP2 gene has 
four exons which generate by alternative splicing two protein isoforms, differing in their N-
termini (Kriaucionis et al., 2004). Duplication of MECP2 lead to the Xq28 duplication 
syndrome, that is mostly reported in males (females are protected by X inactivation) and is 
often associated with ASD or autistic features (Ramocki et al., 2009) (Betancur et al., 
2011). 
 
A particularly intriguing form of autism is a PTEN (phosphatase and tensin homolog) 
macrocephaly syndrome (Butler et al., 2005) (Miles et al., 2011). The frequency 
of PTEN mutations in children with ASD and macrocephaly is unknown; in one study, 15% 
(4/26) of children with PTEN mutations had ASD (Betancur et al., 2011)(McBride et al., 
2010).  More recently, heterozygous PTEN gene mutations have been identified in a 
subset of individuals with autism and macrocephaly (Butler et al., 2005). PTEN is a major 
lipid 3-phosphatase, which signals down the PI3 kinase/AKT pro-apoptotic pathway   
PTEN acts dephosphorylating both serine and threonine residues and regulating various 
cell-survival pathways, such as the mitogen-activated kinase (MAPK) pathway (Waite et 
al., 2002). The protein-phosphatase/MAPK pathway is important in the mediation of growth 
arrest and other crucial cellular functions.  
 
Phelan-McDermid syndrome (PMS) is associated to ASD and schizophrenia and is 
characterized by severe intellectual disability (ID) and poor language (Guilmatre et al., 
2014). In this syndrome a deletion of SHANK3 (22q13 deletion) has been described  
(Berkel et al., 2010)(Durand et al., 2007) (Miles, 2011). Studies demonstrated that 
SHANK3 mutations and the small cytogenetic rearrangements have been implicated with 
an ASD phenotype (Durand et al., 2007).  
 
The most common single gene mutation in ASD is FMR1 associated with FXS, present in 
∼2% of cases. FMRP gene, located on chromosome Xq27-3, is expressed in brain tissue, 
with the highest concentrations in the granular layers of the hippocampus and the 
cerebellum (Abrams et al., 1995). FXS is caused by the expansion of the CGG 
trinucleotide repeat in the 5' untranslated region of the FMR1 gene, which activate the 
hypermethylation inducing partial or complete gene silencing. This alteration leads to 
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partial or complete lack of the gene which product fragile X mental retardation protein 
(FMRP) (Agnes Cristina Fett-Conte, 2013). The FMR1 gene encodes for FMRP (Bassell et 
al., 2008) (De Rubeis et al., 2012), an RNA-binding protein that contributes to the post-
transcriptional control of gene expression. In neurons, FMRP is part of messenger 
ribonucleoparticles (mRNPs) and its functions are multiple, such as, role in the RNA 
metabolism, dendritic targeting of mRNAs, protein synthesis and in particular, regulates 
dendritic transport of associated mRNAs, their stability and local translation (Darnell & 
Richter, 2012)(De Rubeis et al., 2012).  
 
Examples of genes with suggestive evidence of ASD association are RELN and EN2. The 
RELN gene codes for the extracellular matrix glycoprotein Reelin, which is involved in 
neuronal migration and lamination of the cerebral cortex during embryogenesis. RELN 
maps to 7q22 human chromosome, a region linked to ASD. Genetic and molecular studies 
showed that Reelin messenger-RNA and its protein are downregulated in cortical, 
hippocampal, and cerebellar neurons of patients affecting by schizophrenia and autism 
(Guidotti et al., 2000)(Fatemi et al., 2001). EN2 codes for the homeobox-containing 
transcription factor Engrailed-2, a key regulator of posterior brain embryonic development.  
The human En2 gene maps to a region of chromosome 7 implicated in ASD susceptibility 
and genome-wide association (GWA) indicated En2 as a candidate gene for ASD (Joyner 
et al., 1991) (Gharani et al., 2004).  
1.1.2 Neuroanatomical abnormalities in ASD 
Neuropathological changes associated to the development of ASD symptoms have been 
shown in several brain areas, however a clear consensus on the exact areas has not been 
reached and several aspects remain open to investigation. Several studies in post mortem 
brain patients, showed abnormal brain growth and white matter abnormalities, which led to 
consider functional connectivity in areas involved in the development of social, 
communication and motor abilities (Baribeau et al., 2013) (Mostofsky et al., 2009). In 
details, neuroimaging studies have shown altered pattern of brain overgrowth in areas of 
the frontal lobe, cerebellum and limbic structures and a volume loss in the corpus callosum 
and cingulum (Baribeau et al., 2013). Investigations have shown also a decreases in both 
cerebellar gray and white matters regions (Baribeau et al., 2013) (Gadad et al., 2013).  
Kemper and Bauman have described three different types of pathological abnormalities in 
autism: alteration in the development of neurons in the forebrain limbic system, a decrease 
in the cerebellar Purkinje cell population and age-related changes in neuronal size and 
number in the cerebellar nuclei and the inferior olive (Kemper et al., 1998) (Romero-
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Munguía, 2011). Several studies reported a significant data on the anatomy alteration in 
ASD. These variations regard the increase of volumes of the caudate, frontal lobe, 
temporal lobe and cerebellum. Purkinje cells loss and atrophy in fetal period have been 
shown predominantly in the posterolateral neocerebellar cortex (Schmahmann et al., 
2004). Loss of Purkinje neurons is correlated with dysfunctions in GABA 
neurotransmission (the main inhibitory neurotransmitter in the brain): Purkinje cells release 
GABA and alterations of these cells could be related to the increase in GAD67 mRNA 
levels in cerebellar interneurons ASD patients  (Yip et al.,2008). All these abnormalities are 
part of some important aspect during development, such as, neuron migration, 
axodendritic outgrowth, synaptogenesis, and pruning (DiCicco-Bloom et al., 2006). These 
observations suggest that delays in neuronal maturation is important in the pathogenesis 
of autism (Pardo et al., 2007)(Minshew et al., 2007).  
Anatomical studies have also shown enlargement of the amygdala in autistic children, a 
phenotype associated with the severity of the social communication deficits and elevated 
anxiety (Haznedar et al., 2000). Neuropathological analysis of the limbic system in autism 
have found decreased neuronal size, increased neuronal packing density, and decreased 
complexity of dendritic arbors in the hippocampus, amygdala, and other limbic structures 
(Schumann et al., 2009)(Gadad et al., 2013). Overall, consistent evidence confirms that 
anatomical abnormalities in amygdala and cortical structure may lead to deficits in 
dendritic spine reorganization and consolidation (Gadad et al., 2013).  Abnormal spine 
generation or deficits in spine reorganization, elimination, and pruning are anatomical traits 
involved in the pathology of autism (Hutsler et al., 2010). 
1.2  GABAergic system 
The major inhibitory neurotransmitter in the adult central nervous system (CNS) of 
vertebrates is γ-aminobutyric acid (GABA). GABA plays a central role in controlling several 
aspects of neuronal development and communications. GABA does not penetrate the 
blood brain barrier (BBB) and it is synthesized directly in the brain from glutamate by the 
glutamic acid decarboxylase enzyme (GAD). In the cerebral cortex, roughly 80% of the 
neurons are excitatory glutamatergic neurons and 20% are inhibitory GABAergic neurons. 
GABAergic neurons contribute to local circuit properties, whereas the majority has long-
range inhibitory projections to other subcortical nuclei or cortical areas (Markram et al., 
2004).  
There are two main enzyme isoforms, GAD65 and GAD67 (Briggs et al., 2011): GAD65 is 
involved in synaptic transmission and it is the major GABA synthetic enzyme in mouse 
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brains. GAD67 is involved in the synthesis of GABA for general metabolic activity (Gogolla 
et al., 2009)(Chattopadhyaya et al., 2007). Levels of GAD expression can be modulated 
post-transcriptionally by GABA: moreover, glutamate can stimulate carrier mediated non-
vesicular GABA release via upregulation of GAD67 (Soghomonian et al., 1998). 
In the central nervous system, GABA is produced and released by inhibitory interneurons: 
these interneurons are defined on the basis of their morphology, electrical activity and 
connectivity (Ascoli et al., 2008). The different interneurons subpopulations are classified 
in: neurons expressing calcium binding proteins such as parvalbumin (PV), calbindin (CB), 
or calretinin (CR) and/or neuropeptides such as somatostatin (SST), vasoactive intestinal 
peptide (VIP), neuropeptide Y (NPY), or cholecystokinin (CCK) (Kelsom et al., 
2013)(Chattopadhyaya et al., 2012a) with distinct electrophysiological and functional 
properties (De Marco García et al., 2011). Purkinje cells are a distinct set of GABAergic 
cells, present in the cerebellum. Cortical GABAergic neurons are generated in the 
progenitor zones of the basal ganglia, the lateral and medial ganglionic eminences (LGE, 
MGE)(Anderson et al., 2001) and from here they migrate in every district of the brain. In 
postnatal stages, GABA is expressed in developing cortex and the migration of these cells 
has been found in multiple forebrain regions (Marín et al., 2003).  
All cortical regions, including the olfactory bulb, olfactory cortex, cortex and hippocampus 
are populated by the GABAergic neurons originating from the basal telencephalon 
(Anderson et al., 2001). Glutamatergic neurons innervate both principal cells and 
GABAergic interneurons, whereas GABAergic cells project to major extra hippocampal 
target and multiples areas, playing a vital role in modulation of the activity of principal cells 
(Jinno et al., 2007) (Jinno et al., 2009). Vesicular inhibitory amino acid transporter (VIAAT) 
load GABA in synaptic vesicles: following release, GABA transporter GAT1 reuptake 
extracellular GABA into the presynaptic interneurons (lesser related GAT2 and GAT3 
transporters). Following reuptake the breakdown of GABA into glutamate is performed by 
GABA transaminase (GABA-T). Genes coding for GABA receptor subunits are site for 
mutations in ASDs (reviewed in Sgadò et al., 2011). GABA activates three major classes 
of receptors, GABAA, GABAB and GABAC receptors, which have different characteristics. 
GABAA and GABAC receptors are ionotropic, while the GABAB receptors are metabotropic. 
The GABAA and GABAC receptors are Cl- channels that mediate fast synaptic inhibition 
(Chebib et al., 1999). These receptors are members of a superfamily of transmitter-gated 
ion channels composed of five subunits that arrange together to form an ion channel. Each 
subunit has four transmembrane domains. All five subunits arrange forming the wall of the 
channel pore with their transmembrane domains. Whereas, GABAB metabotropic 
receptors are seven transmembrane receptors that activate a second messenger systems 
mediated by phospholipase C and adenylate cyclase and activate K+ and Ca2+ ion 
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channels. These receptors produce slow, prolonged inhibitory signals and function to 
modulate the release of neurotransmitters (Chebib et al., 1999). 
During the embryonic period, GABAA depolarizes the target cells (i.e., excitation) due to a 
relatively high concentration of intracellular Cl-; this characteristic is due to low expression 
of the K-Cl cotransporter KCC2 compared to the expression of the Na-K-2Cl cotransporter 
NKCC1 in immature neurons. Activation of GABA-gated Cl- channels receptors by GABA 
(GABAA receptors) causes the depolarization of the target postsynaptic neurons and a 
GABA-mediated calcium influx that increases the intracellular Ca+ concentration (Cellot et 
al., 2013) (Pizzarelli et al., 2011). GABA excitation may be important for plasticity, synaptic 
connections, and for establishing neural networks.  
During maturation, GABA acts in a opposite effect: Cl- ions are pumped out of maturing 
neurons, such that the binding of GABA to its GABAA receptors cause the 
hyperpolarization of the membrane, therefore GABA switch during development from an 
excitatory to an inhibitory neurotransmission (Ben-Ari et al., 2002) (Schmitz et al., 2005). 
GABA regulates a variety of different developmental processes from cell proliferation 
migration, differentiation, synapse maturation, and cell death (Pizzarelli et al., 2011).  
The balance of excitation to inhibition is controlled by the regulated activities of 
glutamatergic and GABAergic neurons: activity levels are regulated by extrinsic excitatory 
(glutamatergic afferents), mixed excitatory/inhibitory (serotonin, norepinephrine, dopamine 
and acetylcholine afferents from the hindbrain, midbrain and basal forebrain, respectively) 
and GABA inhibitory inputs (Rubenstein et al., 2003).  
An important property of GABAergic innervation is the control of subcellular organization of 
glutamatergic synapses (Huang et al., 2007): alteration in GABAergic synapses may affect 
cortical processing and plasticity. Interneuron subtypes provide specific functions in the 
innervation of distinct domains of the postsynaptic glutamatergic cells (Huang et al., 2007).  
Several studies showed that impaired maturation of the GABAergic circuitry results in an 
immature structure and function of the cerebral cortex that remains more plastic in 
particular in the modulation sensory inputs. An immature structure and function of the 
cerebral cortex is considered a major feature of neurodevelopmental disorders (Sgadò et 
al.,2011). Indeed, disruption of the balance of neural circuits is a cause of neuropsychiatric 
disorders, such as epilepsy, autism spectrum disorders, and intellectual disabilities 
(Kelsom et al., 2013). Disturbances in the development of GABAergic interneurons by 
genetic or epigenetic factors might alter the assembly or plasticity of neural circuits and 
lead to aberrant information processing (Huang et al., 2007). 
Recent studies have found new strategies and new approaches, which could reestablish 
cortical plasticity by manipulating GABA signaling in adult patients with 
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neurodevelopmental disorders (Le Magueresse et al., 2013). Pharmacological tools based 
on the identification of altered molecular pathways are the starting point of these studies.  
1.2.1 Specification of GABAergic interneuron subtypes 
GABAergic neurotransmission contributes to the development of the brain from early 
embryonic stage to adulthood, mediating the shaping and functional maturation of cortical 
networks (Le Magueresse et al., 2013). The site of origin of glutamatergic and GABAergic 
cells is different, whereas the generation of interneurons overlaps with the generation of 
excitatory neurons (Le Magueresse et al., 2013). Murine pyramidal cells originate in the 
ventricular zone of the dorsal telencephalon from E11 to E17, whereas interneurons 
derived from the ganglionic eminences of the ventral telencephalon from E11 to E15 
(Mitsuhashi et al., 2009). GABA immunoreactivity exists at E14 in the cortical plate but 
exhibits its mature pattern only postnatally; the pattern of GABA immunoreactivity is similar 
to that of the adult brain around P16–P21 time (Le Magueresse et al., 2013).The 
maturation of the GABAergic circuitry starts earlier than the maturation of the glutamatergic 
system, and continues for a longer period, proceeding in distinct steps.  
GABAergic neurons have different spatial and temporal origins and belong to three groups 
defined by the expression of parvalbumin (PV), somatostatin (SST), and the ionotropic 
serotonin receptor 5HT3a (5HT3aR) (Rossignol et al., 2011)(Rudy et al.,2011). Interneuron 
specialization also arises from their ability to innervate specific subcellular regions of their 
target cells.  
Parvalbumin interneurons (PV) 
There are two anatomically distinct subgroups of PV neurons: basket cells and chandelier 
cells and these cells has been associated with the fast-spiking (FS) firing pattern (Rudy et 
al., 2011). Multipolar bursting (MB) neurons define a possible subgroup of non-FS, PV-
expressing neurons (Rossignol, 2011) (Kelsom et al., 2013). Within the CA1 region of the 
hippocampal formation, basket cells and chandelier cells make up approximately 75% of 
the total interneuron population (Szilágyi et al., 2011). PV cells play an important role in 
regulating the delicate balance between excitatory and inhibitory inputs in the cerebral 
cortex (Kelsom et al., 2013). Basket cells selectively innervate the soma and proximal 
dendrites, whereas, chandelier cells the axon initial segment of pyramidal cells (Huang et 
al., 2007). 
Basket cells have been involved in two important roles: the initiation of a critical period for 
cortical plasticity and the generation and synchronization of gamma (γ)-oscillations in the 
hippocampus and neocortex (Gogolla et al., 2009). Both phenomena have been suggested 
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to be impaired in the cognitive developmental disorders, such as ASD (Gogolla et al., 
2009). Plasticity and cortical connections in autism disorder may be impaired by disruption 
of PV cell, indeed, different studies demonstrate that PV interneurons have a role in the 
etiology of autism spectrum disorder and other neurodevelopmental disorder during 
development (Chattopadhyaya et al., 2012)(Le Magueresse et al., 2013) (Sgadò et al., 
2011). It is crucial to study the physiological morphological maturation of PV 
positive interneurons in animal models of ASDs (Le Magueresse et al., 2013).  
During late gestation, Chandelier cells (ChCs) derive from the ventral germinal zone of the 
lateral ventricle and require the homeodomain protein Nkx2.1 for their specification 
(Taniguchi et al., 2013). Both basket cells and chandelier cells are fast-spiking, but they 
differ in electrophysiological properties: at present, the function of chandelier cells is 
controversial (Kelsom et al., 2013) (Woodruff et al., 2009). ChCs are characterized 
morphologically by their cartridges forming synapses on the axon initial segment (AIS) of 
pyramidal cells. A single ChC innervates hundreds of pyramidal cells and may exert 
influential control over the spiking of a pyramidal cells (Taniguchi et al., 2013).  PV-cells 
form numerous synapses onto the somata of pyramidal cells, which in turn enrich these 
sites with GABAA receptors and this makes PV-cells perfectly situated to detect changes in 
sensory input, to regulate the spiking of excitatory pyramidal cells, and to synchronize 
brain regions.  
Somatostatin interneurons (SOM) 
Somatostatin interneurons originate from the medial ganglion eminence (MGE) and are 
characterized by two subgroups: Martinotti cells, which account for the majority of SST 
neurons and, less frequently, express other neuropeptides and calcium binding proteins, 
including CR (expressed in layer IV) (Wang Y., et al., 2004)(Marín et al., 2012). The 
colocalization of SST and CR is common in mouse cortical inhibitory neurons and there 
are two subtypes of SST cells: SST/CR+ and SST/CR- cells. Although both SST/CR+ cells 
and SST/CR- cells exhibit similar anatomical features and have similar adapting spike-
firing patterns, they differ in the horizontal extension of their dendritic fields and number of 
primary processes (Xu et al., 2006). These informations suggest that CR cells are a 
distinct subtype of inhibitory neuron present in mouse cortex, or are a distinct variant of a 
similar cell type, likely Martinotti cells. SST/CR+ SST/CR- cells could be defined as a 
subpopulation of non-pyramidal cells (Rudy et al., 2011) (Batista-Brito et al., 2009). SST 
expressing interneurons selectively innervate distal dendrites of target neurons (Huang et 
al., 2007). 
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Neuropeptide Y (NPY) 
NPY is a 36-amino acid neuropeptide that acts as a neurotransmitter in the brain and is 
widely expressed in neural tissue of nervous system (Lundberg et al., 1984). In the brain, it 
is produced by GABAergic system and it is presents in various locations including the 
hypothalamus (Freund et al., 1996). NPY have several functions, including: reducing 
anxiety and stress, reducing pain perception, affecting the circadian rhythm, in the 
neurodegenerative disease and in controlling epileptic seizures (Benarroch, 2009) 
(Cheung et al., 2012) (Kovac et al., 2013). NPY-positive neurons are located both in the 
principal cell layers and the basal dendritic layers.  
 
Fig1.1. Simplify representation of four GABAergic interneurons in mouse cerebral cortex.  
Parvalbumin (PV) containing basket and chandelier cells. In orange, Somatostatin (SST) containing 
interneurons: many of these neurons have the morphology of Martinotti cells. This population includes 
several classes of interneurons that may also express Reelin, CR and/or NPY. Then, there are cells 
expressing very frequently VIP, and many of them also contain CR. Rapidly adapting interneurons with 
multipolar morphologies. Most of these cells express Reelin but not SST, and many also express NPY 
(Marín, 2012). 
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1.2.2 GABAergic dysfunction in the pathophysiology of ASD 
GABA is the only neurotransmitter in the brain, that has an important role in early neuronal 
development (Palmen et al., 2004). During the early neonatal period, GABA provides most 
of the excitatory drive to developing neurons rather than being an inhibitory 
neurotransmitter (Ben-Ari, 2002)(Cherubini et al., 1991; Barker et al., 1998)(Rubenstein & 
Merzenich, 2003).  
Blatt and colleagues (Blatt et al., 2001) investigated four neurotransmitter systems (i.e. the 
GABAergic, serotonergic, cholinergic and glutamatergic system) in the hippocampus of 
autistic adult male and control cases. The result obtained was that GABAergic system was 
the only neurotransmitter system found to be significantly reduced in autism (Blatt et al., 
2001).  
Studies on human postmortem brain tissue have described alterations in different aspects 
of GABA synthesis and release and also in the expression of particular subtypes of GABAA 
receptors (Pizzarelli & Cherubini, 2011). An altered excitation/inhibition (E/I) balance may 
be caused not only by a decreased GABAA-mediated inhibition but also by an enhanced 
GABAA-mediated excitation (Selby et al. 2007). 
Cortical GABAergic neurons in rodents are largely produced in the MGE and migrate 
tangentially to the cortex (Nadarajah & Parnavelas, 2002)(Wonders & Anderson, 2006). 
Defects in the production or migration of cortical GABAergic neurons lead to decreased 
numbers of GABAergic neurons, leading to a hyper-excitable state (Pleasure et al., 2000) 
(Mostofsky et al., 2009). The balance of excitatory vs. inhibitory cells is controlled by the 
relative numbers and activities of glutamatergic and GABAergic neurons (Rubenstein & 
Merzenich, 2003).  Interestingly, immunocytochemical data obtained from human autistic 
brain have revealed an increased density of calbindin-, calretinin-, and parvalbumin-
positive interneurons in the hippocampus, a condition that would alter neuronal signaling 
and synchronization leading to cognitive dysfunctions (Lawrence et al. 2010).  
The disruption of inhibitory circuits may delay critical periods in specific ASDs brain 
regions, thus perturbing γ-oscillations implicated in high cognitive functions (Hensch, 
2005). GABA synthesis and signaling has been shown to regulate the maturation of 
GABAergic innervation also in visual cortex and the onset of critical period plasticity 
suggest that alteration of GABA synthesis, either due to genetic or environmental causes, 
can potentially affect nearly all stages of cortical circuit formation, thereby leading to 
impaired brain development (Chattopadhyaya et al., 2011). Recent studies have 
demonstrated that some drugs may act on GABAergic synapses rescuing behavioral 
deficits in animal models of autism and ameliorating some of the symptoms observed in 
ASD patients (Cellot & Cherubini, 2014).  
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Several genes regulate the process of GABAergic neurons development and an alteration 
in these genetic factors may affect ASD patients (Sgadò et al., 2011). Mutations affecting 
the GABAergic system concern the homeobox genes Dlx1 and Dlx2 (Wonders & 
Anderson, 2006), which, encode homeodomain-containing transcription factors. These 
genes are located on chromosome 2q31, a region previously associated to autism 
susceptibility in several genome-wide linkage studies. A strong association with ASD has 
been demonstrated with the genetic variation of these genes which are associated with 
abnormalities in the development of GABAergic neurons (Chang et al.2011) (Schmitz et 
al., 2005). Among the numerous ASD associated genes, En2 (coding for the homeobox-
containing transcription factor Engrailed-2) was originally shown to be involved in posterior 
brain (mesencephalon/hindbrain) embryonic development (Tripathi et al., 2009).  
GABAergic and synaptic alterations in ASD mouse models. 
Mouse models of neuropsychiatric diseases are designed to have comparable human 
symptoms and possess similarity to the underlying causes of the disease. Results of 
treatments on these animals offer the responses of effect in the human disease. 
Behavioral phenotype provides an approach to the validity of these mouse models for the 
autistic disorder (Moy et al., 2006)(Llaneza et al., 2010): individuals with ASD have life-
long difficulties and environmental stressors and may suffer from seizures. There are 
distinct differences between high- and low-functioning individuals and different 
interventions may be used to improve behaviors (Crawley, 2004) (Paul, 2008). In detail, 
higher-functioning individuals diagnosed with ASD have minor issues with communication 
and sociability (Crawley, 2004). Whereas, lower-functioning individuals demonstrate 
obstacle to communicate that it impairs their ability to obtain basic needs (Paul, 2008).  
ASD severity is based on social communication impairments and restrictive, repetitive 
patterns of behavior; other behavioral alterations include increased anxiety, stereotypic 
forelimb movements and progressive motor dysfunction with, in particular, impaired 
balance and coordination, tremors and impaired postural reflexes (Santos et al. 
2007)(Moretti & Zoghbi, 2006)(Katz et al., 2012) (Stearns et al., 2007) (Gadad et al., 2013) 
(Katz et al., 2012) (Downs et al., 2010).  
In recent years several mouse strains with targeted mutation of specific genes related to 
ASD have been generated that show a number of phenotypical alterations relevant for 
ASD (Marín, 2012)(Bauman & Kemper, 2005; Chattopadhyaya et al., 2012; Rossignol et 
al., 2011) (Provenzano et al.2012). A comprehensive list of the available mouse models for 
ASD is present in SFARIgene database (https:// gene.sfari.org). Different studies have 
been conducted to define the degree of correspondence between ASD and corresponding 
mouse models. These studies indicate that ASD mice generally have profound 
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impairments in inhibition, information processing and seizures susceptibility (Sgadò et al., 
2011) In accordance with human observations, animal studies have revealed important 
dysfunctions in GABAergic signaling occurring at different locations of the GABAergic 
synapses (Paluszkiewicz et al. 2011). Defects in the development and function of 
GABAergic interneurons are associated to a pathogenic mechanism of ASD syndromes.  
GABAergic alteration represents a common aspect in different neurodevelopmental 
disorders, such as, in Rett syndrome and FXS models. Different variations existing in 
patients have been found in Mecp2 mouse model (Neul, 2012). These animals exhibit 
reduction in glutamic acid decarboxylase 1 (Gad1) and glutamic acid decarboxylase 2 
(Gad2) mRNA encoding for GAD67 and GAD65 (Dani et al., 2005)(Chao et al., 2010). 
Therefore, an excitation/inhibition imbalance has been demonstrated in this mouse model 
and it may be due to the depression of GABAergic transmission at both pre- and post-
synaptic levels (Medrihan et al., 2008)(Cellot & Cherubini, 2014). In detail, in MecP2 mice, 
synaptic plasticity processes are correlated with a decrease in GABA and inhibitory 
neurotransmission, demonstrated also by the impairment of long-term potentiation (LTP) 
(Pizzarelli & Cherubini, 2011). Mouse models based on a null allele of the Mecp2 locus 
demonstrate a phenotype consistent with the human disease Rett syndrome, 
characterized by intellectual disability and elevated incidences of ASD (Dani et al., 2005). 
These results indicate that defects in GABAergic neurons reproduce many of the clinical 
features of Rett‘s syndrome (Marín, 2012). 
 
We can assume that GABAergic dysfunction has been implicated in a number of disease 
states involving synaptic and circuit alterations: the parallelism between FXS and other 
developmental disorders is particularly interesting (Paluszkiewicz et al., 2011). Impairment 
in synaptic and GABAergic circuitry has been reported in animal model of fragile X 
syndrome (FXS). These defects contribute to the hyperexcitable circuit phenotype 
(Paluszkiewicz et al., 2011). Studies on Fmr1 knock-out mice show anatomical alteration, 
such as, abnormally cortical dendritic spines, and also altered social interactions, all 
features similar to those observed in autism (Pizzarelli & Cherubini, 2011) (Selby et al., 
2007) (Chonchaiya et al., 2012) (Gadad et al., 2013). Improper synaptic pruning and 
maturation suggest an important role of FMRP at the synaptic level during development 
(Churchill et al., 2002). Fmr1 null mice present, also, alteration in neuron 
and glia differentiation and an abnormal glutamatergic neurogenesis (Castrén et al. 2012).  
 
Mice carrying the R451C mutation in the Nlgn3 gene show behavioral phenotypes related 
to ASD mice. They present an increase in the number of GABAergic synapses and in the 
amplitude of inhibitory currents (Tabuchi et al., 2007). Studies on GABAergic circuit in the 
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hippocampus of these mice demonstrate a decreased GABA release of parvalbumin-
positive (PV) basket cells, which determines an alteration of the excitatory/inhibitory 
balance (Földy et al. 2013). These altered aspects could be identified also in autistic 
children (Curatolo et al., 2014). As Neuroligins, in association with neurorexins, controls 
the formation of both excitatory and inhibitory synapses. They may contribute to alter the 
balance between excitatory synapses and inhibitory synapses that in turn could affect 
cognition and social behavior (Gogolla et al., 2009).  
 
SHANK mutations account for ∼1% of patients with ASD with a severity in cognitive 
impairment; in particular, a high frequency and penetrance of SHANK3 mutations has 
been observed in individuals with ASD (Leblond et al., 2014) (Marín, 2012). SHANK3 has 
an important role in development and function of the glutamatergic neurotransmission onto 
GABAergic neurons (Peça et al., 2011) (Marín, 2012). In cultured hippocampal neurons, 
knockdown of SHANK3 leads to a reduced number and of dendritic spines, decreasing 
spiny density, whereas transfection of SHANK3 in neurons induces the formation of 
dendritic spines with functional synapses (Chen et al., 2014)(Betancur et al., 2009). 
1.3 Brain-derived Neurotrophic factor (BDNF) 
1.3.1 Neurotrophins  
Levi-Montalcini and Hamburger discovered that a mouse sarcoma tumor implanted close 
to the spinal cord of developing chicken secreted a soluble factor that induced the 
hypertrophy and fiber outgrowth of sympathetic neurons. The factor identified by in vitro 
studies was the nerve growth factor (NGF) (Cohen & Levi-Montalcini, 1956)(Lessmann et 
al., 2003). Subsequent studies by Barde and colleagues discovered a neuron specific 
survival factor from pig brain, which was named brain-derived neurotrophic factor (BDNF) 
(Barde et al., 1982). BDNF has a highly homologous in protein sequence to NGF 
(Reichardt, 2006) (Leibrock et al., 1989).  
Since then, other members of the family of neurotrophins (NTs) have been identified: 
neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6) and neurotrophin-
7 (NT-7), these latter have been found only in fish (Lai et al. 1998).  
Neurotrophins have different roles in development and function of the nervous system. 
They promote the control of cell fate, axon growth and guidance, dendrite structure and 
pruning, synapse formation, synaptic plasticity and survival of neurons during the 
development of the central and peripheral nervous systems (Poo, 2001) (Reichardt, 2006). 
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In rodents there are 22 BDNF transcripts all encoding the same protein: eleven different 
5‘UTRs are generated by nine exons (1–9a). Each 5‘UTR is alternatively spliced to a 
common downstream exon 9 containing the coding region and a 3‘UTR with two 
polyadenylation sites (Aid et al. 2007) (Baj et al., 2013). Tongiorgi and colleagues 
demonstrated that BDNF mRNAs are targeted to the distal dendrites in response to tetanic 
electrical activity or other stimuli as BDNF itself (Tongiorgi et al. 1997). Interestingly, it was 
noticed that the translation of BDNF in the soma, proximal, or distal dendrite is due to 
differential trafficking of BDNF mRNA variants to define a  ‗‗spatial code hypothesis of 
BDNF splice variants‖ (Baj et al., 2013) (Chiaruttini et al. 2008). Different transcripts have 
different spatial and temporal localization in the neuronal districts suggesting different 
localizations and biological functions. Indeed, studies demonstrated that some elements of 
the translational machinery (rough endoplasmic reticulum and the Golgi apparatus) have 
been found within dendrites, leading an evidence of local protein synthesis in postsynaptic 
dendrites (Poo, 2001).  
 
All NTs are generated as pre-pro-neurotrophin precursors, which are processed and 
secreted as mature homodimeric proteins into the extracellular space (Lessmann et al., 
2003). BDNF mRNA is designate to ER and the synthesized pro-protein is then packed in 
transport vesicles and accumulates in the membrane stacks of the trans-Golgi network 
(TGN). NTs can be sorted to the constitutive pathway, where secretory vesicles are 
transported by default to cell periphery, or to the regulated pathway, dependent upon 
calcium regulation (Malcangio & Lessmann, 2003). After cleavage the resulting protein is a 
32-kDa proBDNF protein. ProBDNF is cleaved intracellularly by enzymes: furin (the 
abundant protein convertase present in all cells) or pro-convertases. Secreted as the 14 
kDa mature BDNF (mBDNF), or secreted as proBDNF and it is then cleaved by 
extracellular proteases, such as metalloproteinases and plasmin, to mBDNF (Lessmann et 
al., 2003)(Cunha et al. 2010) (Fig. 1.2). 
In the mammalian brain there are four neurotrophins receptors: Trk tyrosine kinases (Trk 
A, Trk B and Trk C) and p75 (p75NTR). p75NTR, is a low-affinity receptor for NGF, 
constituted by an extracellular domain, a single transmembrane domain and a cytoplasmic 
domain (Reichardt, 2006). p75NTR binds each of the neurotrophins with a similar affinity to 
NGF (Dechant & Barde, 2002). 
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Fig 1.2. Schematic representation of BDNF route from synthesis to secretion (Lessmann et al., 2003). 
 
Trk receptors are activated by one or more NTs and are responsible for mediating most 
cellular responses: in detail, TrkA is activated by NGF, TrkB by BDNF and NT-4/5, and 
TrkC by NT-3.  
p75 can be activated by the binding of all four neurotrophins with approximately equal 
affinity, even if it is lower than Trk receptors (Reichardt, 2006). The most abundant TrkB 
isoforms in the brain are the full-length TrkB receptor and two truncated isoforms of this 
receptor, TrkB. T1 and TrkB.T2, generated by alternative splicing. The truncated isoforms 
lack the intracellular catalytic domain (Baxter et al., 1997) (Wong et al. 2013). Trk 
receptors control the activity of several intracellular signaling pathways, including those of 
the Ras/ERK and PI3K/Akt kinase cascades (Patapoutian & Reichardt, 2001). 
NTs bind to axonal Trk and p75 receptors, becoming endocytosed and retrogradely 
transported from the axon to the cell soma where they can activate survival promoting 
cellular signaling cascades (Lessmann et al., 2003) (Poo, 2001). BDNF is involved in the 
cell proliferation and cell survival and have an important role during CNS repair (Zhang et 
al., 2003). The level of NTs at synaptic sites may in principle be regulated by two 
mechanisms: the transport and targeting of NT-containing vesicles to the synapse and the 
synaptic level of NTs regulated by local translation of NT mRNAs.  
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1.3.2 BDNF receptors and signaling 
There is evidence that all the synaptic effects of BDNF are attributed to TrkB activation: 
however, proBDNF binds p75 receptor preferentially, which has distinct functional 
consequences. The binding of BDNF to TrkB truncated variant receptors can act as a 
dominant-negative inhibitor of BDNF signalling by forming heterodimers with the full-length 
TrkB, and by internalizing BDNF to function as a clearance receptor. Therefore, ProBDNF, 
p75 and truncated TrkB isoforms may be considered as negative regulatory mechanisms, 
with consequent effects for synaptic plasticity and perhaps learning and memory (Cunha et 
al., 2010). 
The binding of BDNF to full-length TrkB leads to TrkB autophosphorylation and 
subsequent activation of a series of intracellular signaling pathways: phospholipase Cγ 
(PLCγ), phosphatidylinositol 3-kinase (PI3K), and the cascade governed by extracellular 
signal-regulated kinases (ERK), member of the mitogen-activated protein kinase (MAPK) 
family (Cunha et al., 2010) (Hartmann et al., 2004) (Patapoutian & Reichardt, 2001). A 
more relevant mechanism is the dendritic trafficking and local translation of trkB mRNA 
promoted by neuronal activity both in vitro and in vivo (Tongiorgi et al., 1997). BDNF and 
TrkB are widely expressed in the developing and adult hippocampus and neocortex: BDNF 
mRNA is present in excitatory pyramidal neurons, but not in GABAergic inhibitory 
interneurons (Rutherford et al.1997), whereas, TrkB is expressed by both classes of 
neurons, although its expression is higher in inhibitory interneurons. This has raised the 
possibility that BDNF-to-TrkB signaling modulates an autoregulatory circuit between 
excitatory pyramidal cells and inhibitory interneurons. Neurotrophic effects such as survival 
and differentiation, require internalization of the ligand–receptor complex, and its 
retrograde transport toward the cell body (Roux & Barker, 2002). BDNF and TrkB signaling 
regulate the dendrites stability directly: they control the members of the Rho family of 
GTPases, which have an important role in regulating formation and stability of dendrites. 
 
Signaling capacity of P75 is dependent on the activation of Trk receptors (Kaplan & Miller, 
2000). Ligand engagement of p75 has been shown to promote survival of some cells and 
apoptosis of others. p75 is present in several central neuronal populations, including spinal 
motor neurons and brain stem motor nuclei, lateral geniculate nucleus, amygdala, cortical 
subplate neurons, as well as Purkinje cells, and cerebellum. Postnatally, p75 levels are 
reduced in most tissues and restricted to neurons of the basal forebrain, caudate/putamen 
neurons, motor neurons, cerebellar Purkinje cells (Roux & Barker, 2002). P75 is involved 
in axonal growth via the cytoskeletal affecting protein Rho; p75 activates Rho, which 
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inhibits axonal elongation. In the absence of TrkB in neuronal culture, p75 promotes 
neuronal apoptosis (Roux & Barker, 2002).  
 
Binding of BDNF to Trk receptor induce its dimerization and autophosphorylation of its 
tyrosine residues in the cytoplasmic domain and stimulate intracellular signaling, activating 
at least three different pathways: the mitogen-activated protein kinase (MAPK) pathway, 
the phosphatidylinositol-3-kinase (PI3K) pathway, and the phospholipase C (PLCγ1) 
pathway (Chao, 2003). In the MAP kinase pathway activation of Shc recruits the G-protein 
RAS that, through adaptors Grb2 and SOS, starts a sequential activation by 
phosphorylation of the MAP kinase cascade; whose elements are Raf (a serine threonine 
kinase), Mek (a mixed specificity kinase) and Erk (a MAP kinase). ERK is translocated into 
the nucleus, where it activates some transcription factor such as cAMP-response-element 
binding protein (CREB). The MAP pathway is fundamental for the normal neuronal 
development, neuronal survival and neurogenesis (Chao, 2003). 
In the PLCϒ pathway, PLCϒ catalyzes the breakdown of phosphatidylinositol 4,5- 
biphosphate (PIP2) to diacyl glycerol (DAG) and inositol (1,4,5) triphosphate (IP3). DAG 
activates several protein kinase C (PKC) isoforms. IP3 signaling through specific receptors 
promotes the release of Ca2+ from the intracellular stores. The rise in the intracellular 
Ca2+ concentration activates Ca2+ sensitive enzymes including Ca-calmoduline kinases II 
(CaMKII) and phosphatases, MAPKs and PI3K. PLC-ϒ pathway is important for many 
brain functions like NT-dependent regulation of synaptic plasticity and learning and 
memory.  
BDNF regulates its own expression through the CaMKII signalling: in the PI3 kinase 
pathway, activated Shc recruits PI3K via adaptor proteins Grb2 and Gab1; otherwise, PI3K 
can be activated by Trk receptors through adaptor protein IRS (Patapoutian & Reichardt, 
2001). PI3K phosporylates phosphoinositol (PI) lipids, generating 3,4,5-triphosphates 
(PIP3). PIP3 recruits two proteins to the plasma membrane and these proteins are Akt 
(PKB) and PDK-1. PI3K pathway is essential for NT-mediated neuronal survival (Kaplan 
and Miller, 2000). 
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Fig 1.3. Neurotrophin receptors signaling. 
Trk receptors mediate differentiation and survival signalling through extracellular signal-regulated kinase 
(ERK), phosphatidylinositol 3-kinase (PI3K) and phospholipase C  (PLC- ) pathways. The p75 receptor 
predominantly signals to activate NF- B and Jun N-terminal kinase (JNK), and modulates RhoA activity 
(Chao, 2003). 
1.3.3 Role of BDNF in GABAergic interneurons specification 
BDNF is considered as a general modulator of transmitter release, including the release of 
GABA (Singh et al., 2006). Endogenous BDNF is released from excitatory neurons in 
activity-dependent manner and transferred from excitatory neurons to postsynaptic 
GABAergic neurons, promoting dendritic development of the latter neurons (Palizvan et al., 
2004). NTs in general play an important role in regulating the level of expression of GABA 
and the morphology of GABA-containing neurons (Marty & Berninger, 1997). 
 Several studies have reported increase in the number or size of GAD-positive terminals 
after BDNF induction (Singh et al., 2006): in neuronal cell culture, a prolonged application 
of BDNF enhanced the formation and maturation of GABAergic synapses (Gottmann et al. 
2009)(Palizvan et al., 2004). In detail, BDNF induces an increased in presynaptic GAD65 
content from hippocampal cultures, an overall cellular enhancement of GAD expression 
(Yamada et al., 2002) and an increase in the size and intensity of GAD positive puncta 
(Henneberger et al., 2005). The effects of BDNF on the GABAergic system vary with the 
exposure time in culture and also with the cell types (Wardle & Poo, 2003). Short treatment 
with BDNF modifies synaptic parameters and induces a depression of inhibitory synaptic 
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transmissions in hippocampal slices, whereas, a longer exposure supports the maturation 
of GABAergic neurons, promotes the establishment of GABAergic synaptic connections 
and increases their strength, upregulating GABA release and GABAA receptor expression 
(Henneberger et al., 2005) (Rutherford et al., 1997) (Tanaka et al.1997) (Yamada et al., 
2002). 
BDNF also regulates GABAA receptor responses by Trk type receptor located in 
postsynaptic neurons (Brunig et al.2001).  Several studies observed that BDNF promotes 
GABAergic neuron development, in some cases without influence glutamatergic circuit. 
Glutamatergic synapses on the other hand are converted from immature into active 
synapses upon BDNF induction (Yamada et al., 2002).  
BDNF may lead to increased synaptogenesis, GABAergic development and GABAergic 
responses through the regulation of KCC2 expression (Aguado et al., 2003). The BDNF-
induced shift of the E/I balance of synaptic input toward will inevitably produce enhanced 
network activity, which may be relevant to the etiology of neurological disorders with 
synaptic dysfunction such as epilepsy, schizophrenia and autism. Indeed the inhibitory 
neurons are the principal target of BDNF action, as GABAergic system appears immature 
and functionally impaired in BDNF knockout mice (lacking one copy of the BDNF gene) 
(Abidin et al. 2008). BDNF null mutant mice show reduced expression of NPY, 
parvalbumin, and calbindin in the cerebral cortex and the hippocampus (Kelsom & Lu, 
2013). Overall, both in vitro and in vivo studies have demonstrated that BDNF may 
influence the maturation of GABAergic inhibitory interneurons in several ways and that 
BDNF is required for dendrite growth of GABAergic interneurons (Marty et al.1997)(Jones 
et al.1994). BDNF can also affects the migration of cortical interneurons, but it is not 
required during dendritic development of cortical inhibitory interneurons (Berghuis et al., 
2006)(Gorski et al. 2003). Transgenic mice overexpressing BDNF in the postnatal 
forebrain do have an accelerated development of PV interneurons (Huang et al., 1999). 
Different studies suggest that BDNF also mediates part of the effects of neuronal activity 
on GABA-containing neurons (Marty et al., 1997). Different data demonstrated that during 
development the number of GABA synapses is regulated by BDNF expression, which is 
itself regulated by physiologic synaptic activity (Marty et al., 1997). Downregulation 
of BDNF expression leads to GABA reduction in layer IV of the barrel cortex, following 
sensory deprivation. While whisker stimulation, for example, induces a marked increase 
in Bdnf mRNA levels in layer IV of the corresponding barrels (Rocamora et al., 1996).  
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1.3.4 BDNF in autism spectrum disorder 
Recent evidence suggests an involvement of BDNF in autism. Several studies in small 
population samples showed an involvement of the BDNF/TrkB signaling pathway in autistic 
children: BDNF levels are increased in the blood, serum and brain, compared with normal 
controls (Nelson et al., 2001) (Perry et al., 2001). Reduced BDNF in the cerebellum may 
be an indicator of aberrant brain development and growth in autism. ―Recent reviews have 
shown that the neuroprotective effect of neurotrophic factor therapy appears to be one of 
the most promising approaches toward effective treatment of neurodegenerative diseases. 
The obstacle in the use of trophic factors is their delivery into the CNS (Poduslo & Curran, 
2005). BDNF proteins do not cross the brain capillary endothelial wall, which forms the 
blood–brain barrier (Sakane & Pardridge, 1997). Neurotrophins should be considered to 
enable receptor-mediated transport across an intact blood–brain barrier in vivo, in order to 
have neuropretective function (Zhang & Pardridge, 2006). Chimeric peptide technology 
has been suggested as one strategy for the noninvasive targeting of neuroprotection 
following intravenous administration (Pardridge W.M., 1997) (Pardridge W.M. et al., 2001). 
Abnormal BDNF expression has been linked to many human diseases, such 
as Huntington's disease, schizophrenia and depression (Chang et al. 2006). Recent result 
suggest an association between BDNF and Mecp2 in vivo and a possible role of BDNF in 
RTT syndrome (Chang et al., 2006). MeCP2 may function in the silencing of BDNF basal 
transcription in activity-suppressed neurons (Chang et al., 2006) and  may contribute to 
defects caused by BDNF deficiency. Indeed, BDNF mRNA levels are reduced 
in MeCP2 null mice and other studies demonstrate that BDNF mRNA levels was lower, 
also, in brain samples from RTT patients (Chapleau et al.2009) (Hashimoto et al., 2006) 
(Miyazaki et al., 2004). Another disorder characterized by the decrease of BDNF mRNA 
levels in the neocortex, is Alzheimer disease (AD). 
Studies confirmed the hypothesis that deficits or imbalances in BDNF isoforms may lead to 
neuropsychiatric disorders: reports indeed showed that a reduction in pro-BDNF 
processing and BDNF secretion correlates with deficits in memory and with cognitive 
decline in mild cognitive impairment (Peng et al. 2005)(Zuccato & Cattaneo, 2009). 
In subjects with autism, the increase in pro-BDNF may be responsible for reduced 
neuronal differentiation and dendritic spines, leading to an altered synaptic connectivity 
and neurotransmitter levels (Garcia et al., 2012). Conversely, a reduction in truncated 
BDNF isoform correlates with cognitive impairment in schizophrenia (Carlino et al., 2011). 
In ASD patients, an increase in pro-BDNF and a reduction in truncated BDNF have been 
reported, leading to serious effects on learning, memory, and attention (Garcia et al., 
2012). In healthy controls, it has been verified an increased concentration during the first 
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years of life that decreases in adulthood (Nickl-Jockschat & Michel, 2011). No alteration in 
BDNF mRNA in fusiform gyrus of subjects with autism, compared with controls (Garcia et 
al., 2012). Despite extensive research, the full impact of possible change in BDNF isoform 
ratios has yet to be determined. 
1.4 Engrailed-2 knockout (En2-/-): a model for ASD 
The Engrailed genes, Engrailed-1 (En1) and Engrailed-2 (En2), are homoeobox containing 
transcription factors, homologue to the Drosophila engrailed. In Drosophila the gene is 
involved in the establishment of the anterior-posterior compartment border in several 
imaginal discs and in body segments (Guillén et al., 1995)(Joyner & Martin, 1987). In 
Drosophila and in mammals, the Engrailed genes play a dual role: in early steps of 
development they participate to the specification of the midbrain/hindbrain region (Joyner 
& Martin, 1987) and regulates cerebellar patterning and connectivity (Sillitoe et al. 2010). 
During developmental stages Engrailed genes contribute to the maintenance of neuronal 
population in these areas.  
 
Engrailed genes have a high homology and seem to compensate for one another. Indeed, 
when the En1 gene is replaced by either En2 (Hanks et al. 1995) or the Drosophila 
engrailed gene (Hanks et al., 1995) the resulting homozygous mice show virtually no brain 
defects. In contrast to the single mutation, the combined mutation of the two genes results 
in dramatic repercussions on the maintenance of neuronal population. En2 homozygous 
mutants are viable and fertile and exhibit only a mild phenotype that appears restricted to 
cerebellum (Joyner et al., 1991). Conversely, homozygous En1 mutants die at birth, with 
severe deletion in the cerebellar and dorsal midbrain tissues. En2-/- mice display a 
decrease in cerebellar size, minor abnormalities of patterning foliation with a reduction in 
the number of Purkinje, granule, deep nuclear, and inferior olive neurons (B Kuemerle, et 
al.1997). Recent analysis indicated that En2 is also expressed in the hippocampus and 
cortex (Tripathi et al., 2009).  
1.4.1 Engrailed-2 gene  
Animal studies have demonstrated that En2 is expressed throughout CNS development 
and regulates numerous cells biological processes implicated in ASD including 
connectivity, excitatory/inhibitory (E/I) circuit balance, and neurotransmitter development 
(Benayed et al., 2005)(Benayed et al., 2009). The homology level of En1 and En2 genes is 
more than 90% at the protein level in the homeodomain region, that confers its 
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transcriptional regulation function (Logan et al., 1992) (Morgan, 2006). There are other four 
regions of similarity (EHs), EH1-EH5, where EH2 and EH3 bind PBX, a second 
homeodomain-containing transcription factor that modifies the DNA binding affinity and 
specificity of Engrailed. The domains EH1 and EH5, however, mediate the transcriptional 
repression recruiting the corepressor Groucho (Tolkunova et al.1998). The homeodomain 
EH4 is a highly conserved sequence of about 60 amino acids common to all classes of 
homeodomain protein, and is composed of three alpha helices, of which the third binds 
double-stranded DNA (Morgan, 2006). Engrailed proteins have other properties among 
which the ability to be secreted by cells and internalized and the ability to bind directly to 
the eukaryotic translation initiation factor 4E (eIF4E), through a sequence localized at the 
N-terminal (Nédélec et al., 2004). 
Two intronic single nucleotide polymorphisms (SNP), rs1861972 and rs1861973, are 
consistently associated with ASD (Jiyeon Choi, 2011)(Benayed et al., 2005)(Gharani et al., 
2004). More recently, evidence was provided that one of these SNPs (rs1861973, A-C 
haplotype) was functional: when tested with a luciferase reporter assay in rat, mouse and 
human cell lines, this SNP markedly affected En2 promoter activity (Benayed et al., 
2009).  For these reasons and for the anatomical phenotype that the En2 mouse mutants 
display, En2 was considered a candidate gene for ASD. Recent study demonstrated that 
epigenetic alterations in En2 promoter are evident in the cerebellum of some individuals 
with autism (James et al., 2014). 
To study the role of the En2 gene during the development, Joyner and 
colleagues generated mice homozygous for a targeted deletion of the En2 homeobox 
region (Joyner et al., 1991). Mutant mice were viable and showed no obvious defects in 
embryonic development, suggesting that this might be due to functional redundancy of En1 
with En2. Mutant mice had abnormal foliation in the adult cerebellum, where normally only 
En2 is expressed (Cheng et al., 2010).  
 
 
 
Fig 1.4. Domains within the En protein (Morgan, 2006). 
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1.4.2 Anatomical and behavioral characterization of En2-/- mice 
Other studies defined the En2 gene as an autism-susceptibility gene based on family 
linkage studies indicating an increased transmission of En2 polymorphic variants from 
parents to affected children (Benayed et al., 2009) (James et al., 2014).  Engrailed-2 (En2) 
is considered to be an autism susceptibility gene based on neuroanatomical parallels 
between autism and cerebellar developmental abnormalities in rodent models (Benayed et 
al., 2005). 
Anatomically, En2 mutant mice display defective cerebellar patterning and a reduction of 
cell types of the olivocerebellar circuit (Purkinje, granule, inferior olive and deep nuclear) 
(Kuemerle et al., 2007). Reduced numbers of Purkinje cells in the cerebellar hemispheres 
have been observed in both childhood and adult cases, in individuals with and without a 
history of seizures or medication usage and appear to be unrelated to cognitive function 
(Bauman & Kemper, 2005). These studies also demonstrate a variable changes in the 
volume of the amygdala with an abnormal enlargement and a reduction in the neuronal 
number (Kuemerle et al., 2007). Amygdaloid regions in En2 mutant mice exhibited defects: 
anterior shift of the amygdaloid complex within the temporal lobe positional may have 
negative effects on cognitive function (Kuemerle et al., 2007). These irregularities in the 
cerebella development (Purkinje cell deficit and abnormal folia) and in the amygdala 
(positional shift in cortical location) might resemble some of those reported in ASD patients 
(Kuemerle et al., 2007).  
In the hippocampus, En2-/- mice exhibit a reduction in parvalbumin and somatostatin 
expression: a feature that may be associated with the increased seizure susceptibility 
shown by these mutants (Tripathi et al., 2009). Recent studies evaluated behavioral 
phenotypes of En2 mutant mice, relevant to the diagnostic and associated symptoms of 
ASD (Brielmaier et al., 2012). Learning and memory deficits are common in ASD, and co-
morbid mental retardation has been identified in autistic individuals (Bhattacharya & Klann, 
2012) (Cheh et al., 2006).  
Brielmaier and colleagues confirmed deficits in cognition in En2 null mice, such as a 
sensorimotor gating impairment and a depression-related phenotype (Brielmaier et al., 
2012) (Cheh et al., 2006). Interestingly, reduced exploration has been observed in both 
autistic children and En2 mutant mice, correlated with cerebellar hypoplasia (Pierce & 
Courchesne, 2001). Their results suggest that En2 mutations lead to deficits in social 
behaviors but not in social communication, confirming the first diagnostic symptom of 
autism, without abnormalities in the communication and repetitive symptom domains 
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(Brielmaier et al., 2012). There is not a genotype difference in neurobehavioral 
development, general health, pain sensitivity, open field locomotor activity, anxiety-like 
behaviors, sensory abilities and pain sensitivity (Brielmaier et al., 2012). 
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2. AIM OF THE THESIS 
En2-/- mice have been proposed as a model for ASD, due to a number of anatomical and 
behavioral features similar to those reported for ASD patients, including ASD-like 
behaviors, increased seizure susceptibility and altered GABAergic innervation of limbic 
circuits. Defects in GABAergic transmission have been hypothesized to underlie the 
symptoms of ASD. This research project first aimed at investigating the effect of En2 
ablation on the maturation of GABAergic interneurons in the hippocampus and cerebral 
cortex, hypothesizing a possible role of En2 in the development and/or maintenance of 
forebrain GABAergic interneurons. Recent bioinformatics analysis of the molecular 
signature of En2-/- hippocampus revealed a significant convergence of neurobiological 
pathways previously linked to ASD. In particular, these studies demonstrated that ablation 
of En2 induces a prevalence of pathways related to seizure and altered synaptic 
transmission, indicating altered synaptic development in these mice. A second aim of the 
project was also to analyze the development of synaptic connections of both GABAergic 
and glutamatergic neurons in vivo and in vitro, and the effects of Brain derived 
neurotrophic factor (BDNF; a neurotrophic factor implicated in cell survival, and synaptic 
connectivity) on the maturation of the GABAergic system in En2-/- mice.  
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3. MATERIALS AND METODHS 
3.1 Animals  
Experiments were conducted in conformity with the European Community Directive 
2010/63/EU and approved by the Italian Ministry of Health. Animals were housed in a 12 hr 
light/dark cycle with food and water available ad libitum. All surgery was performed under 
chloral hydrate anesthesia, and all efforts were made to minimize suffering. The generation 
of En2-/- mice was previously described (Joyner et al., 1991). The original En2 mutants 
(mixed 129Sv x C57BL/6 and outbred genetic background) were crossed at least five 
times into a C57BL/6 background. Heterozygous mating (En2+/- x En2+/-) was used to 
generate the En2+/+ (wild type, WT) and En2-/- littermates used in this study. In the 
knockout the cerebellum is reduced in size and cell counts have determined a ~30-40% 
reduction in all the major cerebellar cell types including Purkinje cells. In this study, we 
also used a mouse line GAD67-GFP (line G42) that we crossed with En2 mice. This 
mouse line selectively express enhanced green fluorescent protein (EGFP) in PV-positive 
basket interneurons (soma, dendrites, and axons) and also in putative presynaptic boutons 
(Chattopadhyaya et al., 2004). PCR genotyping, for these mice lines, was performed 
according to the protocol available on the Jackson Laboratory website 
http://jaxmice.jax.org/strain/002657.html and http://jaxmice.jax.org/strain/007677.html). For 
all the experiments, WT and En2-/- age-matched adult littermates (3-5 months old; weight 
= 25-35 g) and young (p30) mice of both sexes were used. 
 
Table 3.1. Primer En2 mouse line: PCR genotyping. Abbreviation as in the text. 
Primer 5' Label Sequence 5' --> 3' 3' Label Primer Type 
12370 - GCCCACAGACCAAATAGGAG - Common 
12371 - TGCAAAGGGGACTGTTTAGG - Wild type Forward 
12372 - ACCGCTTCCTCGTGCTTTAC - Mutant Forward 
 
Table 3.2. Primer GAD67-GFP (line G42) mouse line: PCR genotyping. Abbreviation as in the text. 
Primer 5' Label Sequence 5' --> 3' 3' Label Primer Type 
10201 - AGTGCTTCAGCCGCTACC - Transgene Forward 
10202 - GAAGATGGTGCGCTCCTG - Transgene Reverse 
13731 FAM TTCAAGTCCGCCATGCCCGAA 
ZEN/IBF
Q 
Tg Probe 
oIMR1544 - CACGTGGGCTCCAGCATT - Control Forward 
oIMR3580 - TCACCAGTCATTTCTGCCTTTG - Control Reverse 
TmoIMR01
05 
Cy5 CCAATGGTCGGGCACTGCTCAA BHQ 2 IC Probe 
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3.2 RNA extraction and quantitative RT-PCR from tissue 
Total RNAs were extracted by Trizol© reagent (Invitrogen) from dissected hippocampi, 
somatosensory cortices, visual cortices and cerebellums from WT and En2-/- adult mice. 
DNAse-treated RNAs were purified and concentrated with RNeasy Mini Kit (Qiagen). 
cDNA was synthesized from pooled RNAs (2 µg) using the SuperScript® VILO™ 
(Invitrogen) according to the manufacturer‘s instructions. Quantitative real-time PCR was 
performed using a Biorad thermal cycler with real-time detection of fluorescence. Individual 
PCR reactions were conducted in a volume of 10 µl using the MESA GREEN qPCR kit 
(Eurogentec SA, Belgium) according to manufacturer‘s instructions. Mouse mitochondrial 
ribosomal protein L41 (Mrpl41) was used as a standard for quantification (Tripathi et al., 
2009). Primers were designed on different exons to avoid amplification of genomic DNA. 
Primer sequences are reported in Table 1. Each PCR cycle consisted of denaturation for 
10 s at 94 ºC, annealing for 20 s at 60 ºC and extension for 30 s at 72 ºC. The 
fluorescence intensity of SYBR green I was read and acquired at 72 ºC after completion of 
the extension step of each cycle. Relative expression values were calculated using the 
Biorad software. Mean cycle threshold values from triplicate experiments (Ct; cycle 
number at which each PCR reaches a predetermined fluorescence threshold, set within 
the linear range of the reactions) were calculated for each marker and L41, and corrected 
for PCR efficiency and inter-run calibration. Ratios of each marker / L41 values were then 
calculated for WT and En2-/- mice. Each experiment was performed at least three times. 
Values are expressed as mean ± SEM. 
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Table 3.3. List of primers used for quantitative Real time PCR. Table of different primers used for the 
experiments, primer forward and primer reverse. L41 is the housekeeping gene, used as reference 
control during the real time procedure. The other primers are: vGlut (excitatory presynaptic transporter), 
vGAT (inhibitory presynaptic transporter), GAD67 (glutamate decarboxylase), CALB (calbindin-
GABAergic interneuron), PV (Parvalbumin-GABAergic interneuron), NPY (neuropeptide Y-GABAergic 
subpopulation), SOM (somatostatin- GABAergic interneuron) and the different BDNF Exon primers. 
BDNF primers (ExonI,II,IV,VI,VII,IXa). 
 
Name Forward primer (5′-3′) Reverse primer (5′-3′) 
L41 GGTTCTCCCTTTCTCCCTTG GCACCCCGACTCTTAGTGAA 
vGLUT CACAGAAAGCCCAGTTCAAC  CATGTTTAGGGTGGAGGTAGC 
vGAT TCACGACAAACCCAAGATCAC GTCTTCGTTCTCCTCGTACAG 
GAD67 TCCAAGAACCTGCTTTCCTG GAGTATGTCTACCACTTCCAGC 
CALB AGATCTGGCTTCATTTCGACG TTCATTTCCGGTGATAGCTCC 
PV TGCTCATCCAAGTTGCAGG GCCACTTTTGTCTTTGTCCAG 
NPY TCACAGAGGCACCCAGAG AGAGATAGAGCGAGGGTCAG 
SOM AGGACGAGATGAGGCTGG CAGGAGTTAAGGAAGAGATATGGG 
ExonI CTTCCAGCATCTGTTGGGGAGACG TTCTGGTCCTCATCCAGCAGC 
ExonII CCAGCGGATTTGTCCGAGGTGG TTCTGGTCCTCATCCAGCAGC 
ExonIV ACCGGTCTTCCCCAGAGCAG TTCTGGTCCTCATCCAGCAGC 
ExonVI AGGGACCAGGAGCGTGACAA TTCTGGTCCTCATCCAGCAGC 
ExonVII CTCTGTCCATCCAGCGCACC TTCTGGTCCTCATCCAGCAGC 
ExonIXa ATGGGCCACATGGTGTCCCCAA TTCTGGTCCTCATCCAGCAGC 
 
3.3 Morphometric analyses 
Bright-field images of the hippocampus and somatosensory cortex were acquired at 10 × 
primary magnification using a Nikon Eclipse 90i microscope and merged using Adobe 
Photoshop software. Morphometric analysis of hippocampal and cortical layers was 
performed according to published protocols (Baj et al., 2012) on 3 to 5 NeuN-stained 
sections per animal, taken at the level of the dorsal hippocampus (n = 4 WT and 5 En2-/-). 
Brain areas were identified according to Franklin and Paxinos (1997). The total thickness 
of hippocampus and somatosensory cortex measured in WT mice did not differ from that of 
C57Bl/6 mice, as from published mouse brain atlases (Franklin and Paxinos, 1997; Allen 
Mouse Brain Atlas)(hippocampal total thickness: WT=1192 ± 30 µm, C57Bl/6 = 1147 ± 
76 μm; somatosensory total thickness: WT = 886 ± 15 μm, C57Bl/6 = 925 ± 50 μm; t-test, 
p > 0.05). 
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3.4 In situ hybridization 
For In situ hybridization, brains from 2 WT and 2 En2-/- adult mice were rapidly removed 
and frozen on dry ice. For digoxygenin (DIG) labelled riboprobes the sagittal cryostat 
sections (20 m thick) were postfixed in 4% PFA, washed in PBS, digested briefly with 
Proteinase K (1μg/ml) in PBS, rinsed twice in PBS then treated with a solution of 
Triethanolamine-HCl/Acetic Anhydride pH 8.0 [0.1M Triethanolamine, 0.25% Acetic 
Anhydride]. The sections were then permeabilised in a solution of PBS supplemented with 
1% Triton-X100 (Merck, Germany) and hybridised in Hybridisation Buffer [50% deionized 
formamide, 5X Sodium Salt Citrate (SSC), 5X Denhard‘s solution, 250μg/ml yeast tRNA, 
500μg/ml salmon sperm or herring sperm DNA] containing 1μg/ml of DIG labelled 
riboprobe, hybridized overnight at 65-75_C depending on the riboprobe specificity. The 
post-hybridization washes consisted of a dilution series of SSC (5X, 2X, 0.2X) at 65_C. 
The sections were then equilibrated and washed in B1 Buffer [100mM Tris pH 7.5, 150mM 
NaCl] and incubated overnight with the anti-digoxygenin AP antibody (Roche Diagnostic, 
Germany), diluted 1:5000 in B1 buffer supplemented with 10% new-born calf serum 
(NCS). Specimens were developed using a pre-formulated AP substrate, BM-purple 
(Roche Diagnostic, Germany). Brain areas were identified according to Franklin and 
Paxinos (1997). For each section, bright-field images of the hippocampus, cerebral cortex 
and cerebellum were acquired at 10x primary magnification using a Zeiss microscope, 
Zeiss Observer Z1. In situ hybridizations on brain sections were conducted in 
contemporary with brain sections from control animals. The DNA template for in vitro 
retrotranscription was amplified by PCR using specific 5' primers bearing the T7 RNA 
polymerase sequence that has such a site in its sequence.  
 
Table 3.4 Primer probes for In situ Hybridization. List of primers used for in vitro retrotranscriptions. The 
table shows the T7 sequence, the BDNF sequences and the amplicon measure. NB. +40 is reported 
because after the first cycle we have the ―integration‖of t3 and t7 ―tails‖ in the amplicon. 
 
Primer T7 sequence Sequence 5' --> 3' Primer Type Amplicon 
Fw_T7Ex1 1  
GCGTAATACG 
ACTCACTATA GGG 
TGGGGGT 
ACTCTGAAAC TCC 
ExonI Forward 515+40 
Fw_T7Ex2BC    
GCGTAATACG 
ACTCACTATA GGG 
GTTTGGT 
CCCCTCATTG AGC 
ExonII Forward 226+40    
Fw T7Ex6 1    
GCGTAATACG 
ACTCACTATA GGG 
CGGCTTG 
GAGAAGGAAA C 
ExonVI Forward 267+40 
Fw T7Ex9a   
GCGTAATACG 
ACTCACTATA GGG 
TCTGGTG 
ACAGCGTGTG CAG 
Exon Ixa Forward 416+40 
Rev T3allE    
CGCATTAACC 
CTCACTAAAG GG 
ACAACCGA 
AGTATGAAAT AACC 
Common Reverse 
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3.5 Immunohistochemistry (IHC) 
Immunohistochemical characterization of postnatal En1 and En2 protein expression was 
performed on four weeks old and adult WT mice. Brains were fixed by transcardial 
perfusion with 4% paraformaldehyde followed by 1 h post-fixation at 4 °C, and 30 μm thick 
cryosections were collected. Optimal En1/2 staining was obtained on four week old mice 
(n=4), whereas a weaker signal was obtained in adult mice (not shown). A total of 13 WT 
and 14 En2-/- adult (3–5 months old) littermates were used for immunohistochemical 
identification of GABAergic interneuron subtypes and morphometric analyses of the 
hippocampus and somatosensory cortex. Brains were fixed by immersion in 4% 
paraformaldehyde and coronal sections (50 μm thick) were cut on a vibratome. Serial 
sections at the level of the dorsal hippocampus were incubated overnight with appropriate 
antibodies as follows: affinity purified rabbit polyclonal anti-En-homeodomain1 that 
recognizes En1 and En2 proteins (αEnhd1; 1:100 dilution); anti-parvalbumin (PV) mouse 
monoclonal (Sigma-Aldrich, USA; 1:2000 dilution); anti-somatostatin (SOM) rabbit 
polyclonal (Bachem, UK; 1:2000 dilution); anti-neuropeptide Y (NPY) rabbit polyclonal 
(Bachem, UK; 1:2000 dilution); anti-calbindin 28kD (CALB) mouse monoclonal (Swant, 
Switzerland; 1:5000 dilution); anti-glutamic acid decarboxylase 67 kDa isoform (GAD67) 
monoclonal (Millipore, USA; 1:500 dilution). Signals were revealed with biotin-conjugated 
secondary antibody and streptavidin conjugated to appropriate fluorophores (AlexaFluor 
488/594, Invitrogen Life Technologies,USA). The immunoistochemical technique in the 
cerebral cortex of Gad1EGFP; En2-/- (n=2) and Gad1EGFP; En2WT (n=2) mice, has been 
performed following the previous IHC protocol. The antibodies concentration: anti-inhibitory 
presynaptic marker (vGAT) rabbit polyclonal (Synaptic System, 1:500 dilution); anti-green 
fluorescent protein (GFP) chicken polyclonal (Life technologies, 1:1000 dilution); anti-
Parvalbumin (PV) mouse monoclonal (Sigma-Aldrich, USA; 1:2000 dilution). For 
morphometric analysis, sections were probed with anti-NeuN mousemonoclonal (Millipore, 
USA; 1:500 dilutions) antibody and signal was revealed by diaminobenzidine staining. 
NeuN staining confirmed cerebellar hypoplasia in En2-/- brains (not shown), according to 
previous studies (Joyner et al., 1991; Kuemerle et al., 1997). 
3.6 Cell counts 
Counts of GAD65/67 in situ mRNA positive cells in the hilus and somatosensory cortex 
were performed on 3 sections per animal (n = 3 WT and 4 En2-/- mice) taken at the level 
of the dorsal hippocampus. Brain areas were identified according to Franklin and Paxinos 
(1997). For each section, bright-field images of the hilus and somatosensory cortex were 
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acquired at 10 × primary magnification using a Nikon Eclipse 90i microscope and merged 
using Adobe Photoshop software. Three to five immunolabelled sections at the level of the 
dorsal hippocampus and somatosensory cortex were analyzed per animal (7 WT and 
9 En2-/- mice). For each section, large images of the hippocampus and cortex were 
acquired at 20 × primary magnification using a Zeiss Axio Observer z1 microscope with a 
motorized stage. Acquisitions were automatically performed using the MosaiX and Z-Stack 
modules of the Zeiss AxioVision software (v4.3.1). Five Z-planes for each image were 
projected into a single sharp one. Fluorescence intensity, exposure time and microscope 
settings were optimized for each marker and then held constant. Cell counts were then 
performed on each image using the ImageJ software. To establish a consistent guideline 
for counting individual cells, only cell densities larger than 5 μm with a clearly visible 
nucleus were counted. Signals smaller than 5 μm were excluded to avoid counting 
neurites, nerve terminals, and false signals. The same counting procedures were then 
followed for both in situ hybridization (GAD65/67) and immunohistochemistry (interneuron 
subtypes) images. To count positive cells in the hilus, the total hilar area was measured 
excluding the granule cell layer. The total area of the hilus did not differ between WT 
and En2-/- mice (WT, 109,780 ± 5032 μm2; En2-/-, 100,958 ± 2602 μm2; t-test, p > 0.05). 
Cell densities were then plotted as the number of positive cells/0.1 mm2. For the 
somatosensory cortex, cell densities were separately counted in superficial (II–III) and 
deep (V–VI) layers. A counting frame with an area of 200 μm × 600 μm was used. The 
sampling field was moved systematically through the cortical layer of interest at least three 
times for each section. CALB-positive interneurons were identified by double-labeling with 
GAD67. Cell densities in the cerebral cortex were plotted as the number of positive 
cells/counting area (200 μm × 600 μm). All counts were performed by two independent 
experimenters blind of genotypes. 
3.7 Analysis of perisomatic innervation. 
Brains were fixed by transcardial perfusion with 4% paraformaldehyde followed by 1 h 
post-fixation at 4 °C, and 75 μm thick sections were collected. Briefly, at least 3 confocal 
images of the perisomatic cells were taken within using a 63X oil objective (Zeiss, NA 1.4) 
and a Zeiss 780 LSM Confocal Microscope. Scans from each channel were collected in 
multiple-track mode and subsequently merged. Care was taken to use the lowest laser 
power and no bleed through was visible between Alexa647, Alexa594 and Alexa488 
channels. Z-stacks were acquired with 1µm steps, exported as TIFF files, and analyzed 
using Fiji Image software. Green and red channels were separated using custom-made 
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macros. The analyses were performed on PV and vGAT immunostaining. Synaptic puncta 
onto GABAergic and glutamatergic soma was selected using a donut-like shape (10 pixels 
size selection brush).  After the subtraction of background, PV and vGAT signal per soma 
was averaged along with their standard error.  Student t-test was used to evaluate the 
statistical differences.  
3.8 Western Blotting analysis 
Protein expression was studied using samples homogenized and processed in Ripa buffer 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 2 mM EDTA, 2 mM PMSF, 5 ug/mL 
leupeptin, 5 ug/mL pepstatin) homogenizing tissue samples in 1 ml of Ripa reagent per 50-
100 mg. RNA extraction continue with the support of Rneasy Lipid tissue mini kit. Total 
protein extracts (30 μg) were separated on 4–12 % NuPage Pre-Cast Gels (Invitrogen), 
transferred to 0.2 mm PVDF membranes. The membranes were washed 10 min in TBS-T, 
pH 7.4 (0.1 M Tris, 0.15 M NaCl) and blocked in 5% nonfat dry milk, in TBS with 0.1% 
Tween 20 (TBST) for 1 h. The incubation with the following primary antibodies, BDNF 
(1:1500 N-20, Santa Cruz), TrkB (1:750- Promega), has been performed at +4 °C O/N. 
The next step has been washed the membranes in TBS-T, incubating with the secondary 
goat anti-mouse HRP antibody (1:10000) for 1 h at RT. 
Detection was performed using ECL chemiluminescence system (GE Healthcare). Protein 
levels were detected using chemiluminescence (BioRad) software and quantitative 
densitometry analysis has been completed using ImageJ software. In some β-Tubulin was 
used as a standard for protein quantification. In BDNF western blotting analyses, the 
normalization for loading was not necessary because we calculated the ratio within 
subject. The specificity of the Western blot results was confirmed by negative controls with 
lysis buffer and PBS in 2× Laemli buffer without the protein extract.  
3.9 Primary neuronal cell culture 
Brains of E18.5 mice were dissected, the meninges were removed and the hippocampi 
were isolated. Hippocampi were transferred in a 15-ml tissue culture tubes for a pooled 
mouse culture. The tissue was resuspended in dissection medium and dissociated 
mechanically in plating medium with a polished tip of glass Pasteur pipettes. Take a 10-μl 
aliquot of the dissociated cells to estimate viable cell density on a hemocytometer. Cells 
were plated adding 90,000 cells to an 18-mm coverslip in a 12-well dish (65 cells per mm2) 
coated with Poly-L-Lysine.  Cells were incubated in the cell culture incubator at 37 °C for 
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2–6 h. Four hours after plating cells, they were examined under the microscope to ensure 
that the cells have settled on the substrate. Gently the medium has been aspirated from 
each well and add 1.5 ml of fresh maintenance medium warmed to 37 °C to each well in 
the 12-well dish. Cells were incubated in a cell culture incubator at 37 °C and the medium 
was changed every 3-4 days (Beaudoin et al., 2012). 
3.10 Immunocytochemistry analyses  
Cells were recovered at day 14 (DIV14) and coverslips were washed for 5 min with PBS 
and then incubated with paraformaldehyde (PFA) 4% solution in PBS for 20 min. The 
slices were washed three times with PBS and incubated with blocking solution for 1h. Cells 
were incubated for 1.5 h with primary antibody in blocking solution and then washed three 
times for 5 min with PBS containing Triton 0.1%. Cells were then incubated for 1 h with 
secondary antibodies, washed again, incubated for 5 min with Hoechst and mounted with 
Aqua Polymount (Polysciences). The primary antibodies used were: vGAT (1:1000, 131 
003, Synaptic System), vGlut2 (1:1000, 135 403, Synaptic System), MAP2 (1:200, 556320, 
BD Bioscience). The secondary antibodies used were: Alexa Fluor 594 Donkey anti-rabbit 
(1:1000; Jackson ImmunoLab, 711-545-152), Alexa Flour 488 Donkey anti-rabbit (1:1000; 
life technologies, A-21207). Images were taken using Confocal, Leica. 
 
The number of synapses in a neuron was calculated using Columbus Image Data Storage 
and Analysis system (PerkinElmer) (v. 2.4.2). The images were uploaded in the system by 
means of Columbus Importer software (v 2.4), using 0.25 µm as pixel size defaults. Based 
on MAP2 staining, cell nuclear region was identified by a texture analysis algorithm. This 
image analysis algorithm or ‗building block‘ analyzes the intensity structure of a defined 
image region for the occurrence of typical patterns. Using a combination of intensity and 
morphology properties, the population of real cell objects was defined. The cell body was 
then estimated by creating a region of interest starting from the cell nuclear region. 
Neurites were detected based on MAP2 staining and assigned to a specific cell body, 
using the bulding block ―Find Neurites‖. Automatically it generates a set of neurite 
properties characterizing each cell‘s neurite tree such as total neurite length, length of 
longest neurite, number of segments, number of extremities, number of roots and number 
of nodes. Furthermore it generated a set of neurite properties related to the neurite 
segment population including the segment length in pixel, the branch level which indicates 
if the segment branched directly from cell body or from another neurite. Based on these 
properties, segments with length less than 5 pixels were excluded. Synapses were 
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quantified on neurites by adding the ―Select Region‖ building block to enlarge the neurite 
region (by choice of pixel) and using the ―Find Spots‖ building block in the selected neurite 
region exploiting the protein vGAT and vGlut2. The algorithm to identify spots was based 
on ―Detection of local intensity maxima‖ as first step. Each object of the output population 
(spots) is characterized by set properties including the corrected spot intensity (the mean 
spot intensity minus spot background intensity) and spot area (the area of the spot region 
in pixel units). For each neurite segment, the synaptic contact was calculated as the ratio 
between the number of spots and the segment length. The differences (―genotype‖ and 
―treatment‖) were evaluated using two-way ANOVA followed by Tukey‘s range test for 
multiple comparisons.  
3.11 Statistical Analysis 
Statistical analyses for RT-qPCR were performed by SigmaStat software. Student‘s t-test 
or ANOVA followed by appropriate post-hoc test (as indicated) were used (WT vs En2-/-), 
with statistical significance level set at p<0.05. Comparisons between two or more groups 
were performed with Student‘s t-test or one-way/two way ANOVA as appropriate, using 
GraphPad Prism 6.0. A p-value < 0.05 was considered to be significant.  
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4. RESULTS 
4.1 Cortical Interneuron characterization in En2-/- mice  
Engrailed protein expression in the postnatal mouse hippocampus and cerebral cortex.  
Neuroanatomical and behavioral studies performed on adult En2-/- mice suggest 
that En2 might be expressed also in anterior brain structures during adulthood (Cheh et al., 
2006) (Kuemerle et al.,2007). Previous studies from our laboratory showed that, in the 
adult mouse brain, En2 mRNA is expressed in the hippocampus and cerebral cortex, two 
regions crucially involved in seizure generation and spread (Tripathi et al., 2009). In order 
to evaluate the expression pattern of Engrailed proteins, we performed 
immunohistochemical analysis, using an antibody that recognizes both En1 and En2 
proteins (αEnhd1) on serial sagittal sections. This expression profile revealed the pattern 
of Engrailed proteins (En1/2) in the postnatal mouse forebrain. In primary somatosensory 
cortex, En1/2 staining was nuclear, according to the transcriptional activity of the Engrailed 
proteins. Double labeling experiments reveals the presence of En1/2 proteins were present 
in PV-positive and CALB-positive interneurons, in the hippocampus and cerebral cortex, 
(Fig.4.1 A, F). 
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Fig.4.1. Immunohistochemical data of En1/En2 protein expression in hippocampus and somatosensory 
cortex.  
A) B) Representative immunostainings of in the somatosensory cortex of adult WT mice (P28). C) D) E) 
Single- channel acquisition of EN (red), CALB (blu) and PV (green) positive interneurons in cortical layer. 
F) G) H) Triple immunostaining showing En (red), PV (green) and CALB (blue) positive cells in the P28 
mouse hippocampus. I) J) K) Single channel acquisitions of En, PV and CALB immunostainings from 
the CA2–CA3 hippocampal regions. Scale bar: 400 μm (A), 700 μm (F,G); 95 μm (B-E); 160 μm (H-K). 
Cortical integrity and morphometric analysis in En2-/- mice 
Given the importance of the Engrailed genes in brain development and patterning of brain 
areas, we examined the morphology of the En2-/- cerebral cortex. NeuN 
immunohistochemistry revealed no gross layering defects in the somatosensory cortex of 
adult En2-/- mice, as compared to WT littermates. Morphometric analysis showed that the 
total thickness of the somatosensory cortex (WT, 886 ± 15 μm; En2-/-, 938 ± 13 μm) as 
well as the thickness of each cortical layer (Fig.4.2.A,B) did not differ between WT 
and En2-/- mice (p > 0.05, two-way ANOVA followed by Holm–Sidak test; n = 4 WT and 
5 En2-/-). 
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Fig 4.2.  Morphometric analysis in the En2-/- somatosensory cortex.  
Normal layering of the En2-/- somatosensory cortex. A) Representative NeuN immunostaining of 
the somatosensory cortex from adult WT and En2-/- mice. B) Morphometric analysis of cortical in WT 
and En2-/- mice. Layer thickness is plotted as % of total cortical thickness. Layers, animal numbers and 
genotypes are as indicated. Scale bar: 120 μm. 
Interneuron subpopulations in the somatosensory cortex of En2-/- and WT mice. 
Several studies showed that alteration of cortical interneuron may play a significant role in 
the development of neurological disorders (Di Cristo, 2007) (Gogolla et al., 2009) (Kelsom 
& Lu, 2013). In cerebral cortex, neurons releasing the neurotransmitter GABA have a 
fundamental role in shaping cortical circuits (Rudy et al., 2011). Disruption of GABA 
synthesis, affecting migration, maturation and synapse formation may lead to impaired 
brain development (Rossignol, 2011) (Di Cristo et al., 2011). Malfunction of these neurons 
has been implicated in a number of diseases, such as epilepsy, schizophrenia, anxiety 
disorders and autism (Cossart et al., 2001)(Cobos et al., 2005)(Rudy et al., 2011). The link 
between dysfunction in GABAergic interneurons and the pathophysiology of 
neurodevelopmental disorders results from an imbalance between excitation and inhibition 
in local circuit. Defective development of GABAergic interneurons and subsequent reduced 
inhibition might contribute to the pathogenesis of ASD (Gogolla et al., 2009) (Pizzarelli & 
Cherubini, 2011)(Chattopadhyaya & Cristo, 2012)(Provenzano, et al., 2012). En2-/- mice 
present a neuroanatomical and behavioral phenotype resembling some features observed 
in ASD (see references in Introduction). In addition, En2-/- mice have an increased 
susceptibility to KA-induced seizures, displaying more severe and prolonged generalized 
seizures as compared to WT mice (Tripathi et al., 2009). Hippocampal En2 mRNA 
decreased after induced seizures, suggesting that En2 might also influence the functioning 
of forebrain areas during adulthood and in response to seizures; more importantly, a 
reduced staining of parvalbumin and somatostatin was detected in the En2-/- 
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hippocampus, suggestive of an excitation/inhibition imbalance in these mutants (Tripathi et 
al., 2009). We therefore decided to investigate the different GABAergic subpopulations in 
somatosensory cortex of En2-/- mice, by studying the expression of GABAergic markers at 
both mRNA and protein level. 
We first performed histological experiments to count the number of GAD, PV, NPY, SOM 
and CALB positive interneurons in the somatosensory cortex of WT and En2-/- mice. The 
number of GAD65/67 positive interneurons was unchanged throughout the somatosensory 
cortex of En2-/- mice, as compared to WT littermates (Fig.4.3, A, B). Following these 
results, we decided to study the distribution of the different interneuron populations in 
mutant mice. In the cerebral cortex, PV and SOM interneurons account for about 70% of 
all interneurons (30% PV, 30% SOM, 10% PV+SOM; (Rudy et al., 2011). The results 
obtained for the different interneuron markers in the somatosensory cortex of WT and En2-
/- littermates, showed a reduction in the number of PV and SOM interneurons, in layers II–
III of the En2-/- cortex, as compared to WT littermates (Fig.4.3, C). In superficial layers, PV 
and SOM interneurons were significantly reduced (PV: −44%, p<0.05; SOM: −25%, 
p<0.001, Student's t-test) (Fig.4.3, D). A significantly reduced number of NPY interneurons 
was detected in both superficial and deep layers of the En2-/- somatosensory cortex, when 
compared to WT littermates (−30% and −42% in layers II–III and V–VI, respectively; 
pb0.05, Student's t-test; Figs. 4.3, C, D). CALB-expressing GABAergic interneurons 
represent a subpopulation of cells present in the cerebral cortex: pyramidal glutamatergic 
neurons also express CALB (Jinno & Kosaka, 2010). We considered the total number of 
CALB-expressing neurons throughout all layers of the somatosensory cortex, concluding 
that there was not difference between WT and En2-/- mice (cells/area in layers II/III: 
WT=178±9, En2-/- =193±6; cells/area in layers V–VI: WT=60±4, En2-/-=57±3; p>0.05, 
Student's t-test). The number of CALB-positive interneurons, identified by GAD67/CALB 
double staining, was also unchanged between the two genotypes (Figs. 4.3, E,F)  p>0.05, 
Student's t-test).  
 
In order to evaluate the mRNA level of different GABAergic markers, we first performed 
quantitative RT-PCR. RT-PCR experiments revealed a different profile of GABAergic 
marker mRNA expression in the somatosensory cortex: a statistically significant decrease 
of PV mRNA expression (−10%) was detected in En2-/- mice as compared to WT 
littermates (Fig.4.3, G; p<0.05, Student's t-test). NPY and SOM mRNA expression was 
unchanged, whereas CALB mRNA expression was significantly decreased (−17%; p<0.01, 
Student's t-test) in mutant mice (Fig.4.3, G). There was no change in mRNA expression 
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levels for glutamic acid decarboxylase (GAD67), vesicular GABA transporter (vGAT) and 
vesicular glutamate transporter (vGlut) between the two genotypes. 
 
 
Fig.4.3 Reduced number of GABAergic interneurons in the En2-/- somatosensory cortex 
A) Representative in situ hybridizations showing GAD65/67 mRNA-positive neurons in the 
somatosensory cortex of adult WT and En2-/- mice. B) GAD65/67 mRNA-positive interneuron cell 
counts. Values are expressed as the mean number (± s.e.m) of positive cells per area (0.12 mm2, see 
Material and Methods). C) Representative immunostainings of PV, NPY and SOM interneurons in the 
somatosensory cortex of adult WT and En2-/- mice. D) PV, NPY and SOM interneuron cell counts 
(values are reported as in B). E) Representative immunostainings of CALB (green) and GAD (red) 
50 
 
positive neurons in the somatosensory cortex of adult WT and En2-/- mice. F) Top: representative GAD 
(red arrowhead), CALB (green arrowhead) and GAD+CALB (white arrowhead) interneurons in layers V-
VI of the En2-/- somatosensory cortex. Bottom: cell counts of CALB/GAD double-positive interneurons in 
the somatosensory cortex of adult WT and En2-/- mice (values are reported as in B). G) Relative 
expression of glutamatergic and GABAergic markers mRNAs in the somatosensory cortex of adult WT 
and En2-/- mice (quantitative RT-PCR). Values are plotted as the mean ± s.e.m of 3 replicates from 
pools of 7 animals per genotype. In all pictures, animal numbers, genotypes and cortical layers are as 
indicated. In all graphs, asterisks indicate statistical significance (*p< 0.05, ***p< 0.001, Student‘s t-test, 
WT vs. En2-/-). Scale bars: 200 μm (A), 85 μm (C,E), 20 μm (F). 
 
Our results show a loss of specific interneuron subpopulations detected by 
immunohistochemistry, which is in agreement with the reduced expression of the 
corresponding GABAergic markers as revealed by quantitative RT-PCR. Our data 
demonstrate that loss of En2 results in a decrease of PV, NPY, and SOM interneuron 
numbers in the somatosensory cortex. Loss of parvalbumin (PV), somatostatin (SST) and 
neuropeptide Y (NPY) interneurons is not, however, associated with a decrease of the total 
number of interneurons expressing GAD and with defects in the laminar structure of these 
areas, indicating that En2 mutation has a very selective and specific effect on different 
subpopulation of GABAergic interneurons.  
Reduction of interneuron subpopulations in visual cortex. 
Previous studies indicated that alterations in visual cortex may be obtained by interfering 
with the GABAergic function (Hensch, 2005)(Pizzarelli & Cherubini, 2011). In the visual 
cortex, GABAergic innervation controls the onset of critical periods during which neuronal 
circuits display a sensitivity to environmental stimuli (Pizzarelli & Cherubini, 2011). In order 
to evaluate the expression of glutamatergic and GABAergic markers in the visual cortex, 
we performed immunohistochemistry analyses and quantitative RT-PCR, in adult 
WT and En2-/- mice. Immunohistochemistry experiments were performed to quantify SOM, 
NPY, and PV positive cells in the primary visual cortex of adult WT and En2-/- mice. 
Immunostaining revealed significant differences in SOM, NPY, and PV positive cell 
densities between WT and En2-/- mice, at adult age.  En2-/- mice showed a lower number 
(−25%) of SOM cells in layers II–III, and a lower number (−20%) of NPY cells in layers V–
VI, as compared to age-matched controls (SOM, p = 0.024, Two-Way ANOVA followed by 
Tukey test; NPY, p = 0.040, Two-Way ANOVA followed by multiple t-test; n =3 per 
genotype; Fig. 4.4,A).   
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Fig.4.4. Profile of GABAergic interneurons in visual cortex, at adult age. 
A) Immunostaining of SOM, NPY and PV positive cells, at the level of the primary visual cortex in 
adult WT (white) and En2-/- (gray) mice. Immunohistochemistry reveal cell densities in layers II–III and 
V–VI are plotted as the mean number (± s.e.m.) of cell per area. A lower density of SOM+ cells was 
detected in the En2-/- visual cortex at adult age. Statistical significance: *p < 0.05; **p < 0.01(WT 
vs. En2-/-). Scale bar = 100 μm. 
 
 
The expression profile of GABAergic marker protein in the visual cortex prompted us to 
investigate the mRNA expression of GABAergic interneurons in the primary visual cortex 
of WT and En2-/- mice in adulthood. vGLUT1 mRNA expression significantly lower in En2-
/- adult mice, as compared to age-matched WT controls (–13% in En2-/-; Two-Way 
ANOVA followed by Tukey test, p < 0.001, n = 4 per genotype). The RT-qPCR revealed a 
decrease expression also in other GABAergic markers, in particular, in SOM, NPY, vGAT 
mRNA levels, in En2-/- mice compared to controls (Fig. 4.5). 
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Fig.4.5.mRNA expression of En2 and glutamatergic/GABAergic markers in the adult visual cortex 
of WT and En2
−/−
 mice. 
A) Relative mRNA expression level as obtained by quantitative RT-PCR performed on the visual cortex 
of adult WT (white) and En2-/- (gray) mice. Values are expressed as each marker/L41 comparative 
quantitation ratios (mean ± s.e.m.). SOM, NPY, vGLUT, and vGAT mRNA levels were higher in adult 
WT mice. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001 (WT vs.En2-/-). Abbreviations as in 
the text. 
Morphometric analysis of the En2-/- visual cortex. 
Morphometric analysis did not reveal any significant difference between WT and En2-/-
 mice analyzed (Fig. 4.6, A) (p > 0.05, Two-Way ANOVA; n =3 per genotype) (Fig.4.6, B). 
NeuN immunohistochemistry also revealed no gross layering defects in the primary visual 
cortex of adult En2-/- mice, as compared to WT littermates (Fig.4.6, C). Morphometric 
analysis showed that at adult age analyzed, the total thickness of the primary visual cortex 
(adult WT, 1018 ± 15.20 μm; adult En2-/-, 985.2 ± 8.95 μm) as well as the thickness of 
each cortical layer (Fig. 4.6, C) did not differ between genotypes (Two-Way ANOVA, p > 
0.05; n = 3 per genotype). 
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Fig.4.6 Normal neuronal density and layering in the primary visual cortex of adult En2-/- mice. 
 A) Representative NeuN immunostaining of the primary visual cortex, in adult WT (white) and En2-/- 
(gray) mice. B) C) Quantiﬁcation of NeuN immunohistochemistry experiments. Cell densities in layers II–
III and V–VI are plotted as the mean number (±s.e.m.) of cell per area (see Materials and Methods). 
Layer thickness is plotted as % of total cortical thickness. Scale bar=100μm. 
4.2 Hippocampal interneuron characterization in En2-/- mice  
Previous studies from our laboratory demonstrated En2 mRNA expression in the adult 
mouse hippocampus; En2-/- mice also showed a staining reduction in PV and SOM 
interneurons in this brain area (Tripathi et al., 2009). We performed a morphometric 
analysis on dorsal hippocampal sections stained for the pan-neuronal marker NeuN. A 
normal anatomical structure of hippocampal layers was detected in WT and En2-/- mice 
(Fig. 4.7, A). Total hippocampal thickness did not differ between WT and En2-/- mice (WT: 
1192 ± 30 μm, n = 4; En2-/-: 1115 ± 28 μm, n = 5; p > 0.05, t-test), and no difference was 
detected in hippocampal layer thickness between the two genotypes (Fig.4.7, B, C; 
p > 0.05, two-way ANOVA). Thus, the decreased GABAergic innervation observed in 
the En2-/- hippocampus (Tripathi et al., 2009) is likely due to specific defects of selected 
interneuron subtypes and not to a general alteration of hippocampal structure. 
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Fig.4.7. Morphometric analysis in the hippocampus of En2-/- mice. 
 A) Representative NeuN immunostaining of the whole dorsal hippocampus from WT and En2-/- mice. B) 
Subdivision of hippocampal layers used for morphometric analyses. C) Morphometric analysis of 
hippocampal layers in WT and En2-/-mice. Layer thickness is plotted as % of dorsal hippocampus total 
thickness. Animal numbers and genotypes are as indicated. Abbreviations: DG, dentate gyrus; Lacun. 
Molec., stratum lacunosum moleculare. NeuN, pan neuronal marker NeuN. Scale bars: 800 μm (A), and 
300 μm (B). 
Hippocampal interneuron characterization in En2-/- mice. 
We then investigated the anatomical profile of GABAergic interneurons in the 
hippocampus of WT and En2-/- mice. We studied the total number of GABAergic neurons 
using GAD65/67 mRNA in situ hybridization. The GABAergic number was unchanged in 
the hilus (Figs.4.8, A, B) of En2-/- mice, as compared to WT littermates.  
Immunohistochemistry experiments revealed a reduction of PV-, NPY-, SOM- but not 
CALB-positive interneurons in the hilus of En2-/- mice, as compared to WT littermates 
(Fig.4.8,A). Quantification of immunohistochemistry experiments confirmed a statistically 
significant reduction of PV, NPY and SOM interneurons in the En2-/- hilus (− 38%, − 14% 
and − 20%, respectively; p < 0.05, Student's t-test; (Fig.4.8, C), whereas no difference was 
detected in the number of CALB interneurons (Fig.4.8, C).  
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RT-qPCR analysis demonstrated a statistically significant decrease of NPY (− 48%), PV 
(− 25%), SOM (− 24%), but not CALB mRNA expression was detected in En2-/- mice as 
compared to WT controls (Fig.4.8, D; p < 0.05, Student's t-test).  
 
 
Fig.4.8. Reduced number of GABAergic interneurons in the En2-/- hilus  
A) Representative pictures showing GAD-, PV-,NPY-, SOM- and CALB-positive interneurons in the hilus 
of adult WT and En2-/- mice. B) GAD-positive hilus interneuron cell counts. Values are expressed as the 
mean number (± s.e.m) of positive cells per area (0.1 mm2, see Materials and methods). C) Subtype-
specific hilus interneuron cell counts. Values are reported as in B). Animal numbers and genotypes are 
as indicated. Asterisk indicates statistical significance (*p < 0.05, Student's t-test, WT vs. En2−/−). D) 
Relative mRNA expression level of glutamatergic and GABAergic markers, as obtained by quantitative 
RT-PCR performed on the whole hippocampus of adult WT and En2-/- mice. Values are expressed as 
each marker/L41 comparative quantitation ratios (mean ± s.e.m of 3 replicates from pools of 7 animals 
per genotype; *p < 0.05, **p < 0.01, Student's t-test, WT vs. En2-/-). Abbreviations: vGLUT, vesicular 
glutamate transporter; vGAT, vesicular GABA transporter; GAD65/67, glutamic acid decarboxylase 
(65/67 kD isoform); PV, parvalbumin; CALB, calbindin; NPY, neuropeptide Y; SOM, somatostatin. Scale 
bar: 300 μm. 
 
We observed that mRNA expression levels for pan-GABAergic (glutamic acid 
decarboxylase, GAD67; vesicular GABA transporter, vGAT) and pan-
glutamatergic (vesicular glutamate transporter, vGLUT) markers did not change between 
the two genotypes (Fig.4.8, D).  
These data indicate that, in the absence of major hippocampal morphological alterations, 
the En2 null mutation results in the selective reduction of PV, NPY, SOM but not CALB 
hilus interneurons. 
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4.3 Synaptic connectivity and dendritic development in En2-/- mice 
Given the GABAergic interneurons dysfunctions in cerebral cortex and hippocampus of our 
mouse model and the importance of synaptic development and connectivity in ASD, we 
studied the interneurons synaptic connections on cortical principal neurons 
(glutamatergic). In particular, we focused our attention on the synaptic connections that PV 
GABAergic interneurons generate with layer V-VI pyramidal neurons. To this purpose, we 
crossed En2 mice with Gad1-EGFP (line G42) mice that selectively express enhanced 
green fluorescent protein (EGFP) in PV-positive basket interneurons (soma, dendrites, and 
axons) and also in putative presynaptic boutons (Chattopadhyaya et al., 2004). However, 
the GFP transgene expression in the synaptic boutons was less intense in our mice 
compared to the original strain, therefore the perisomatic innervation was analyzed using 
PV antibody (Chattopadhyaya et al., 2004). 
We performed immunohistochemical technique in the cerebral cortex of Gad1EGFP; En2-
/- (Fig. 4.9, A) and Gad1EGFP; WT mice (Fig. 4.9,B). The immunostaining revealed PV-
positive interneurons labeled in red, vGAT (inhibitory presynaptic marker) in blue (Fig. 4.9) 
and GFP (expressed in basket cells) in green (not shown in this analysis). We analyzed 
PV and vGAT spine density, considering the intensity of puncta staining of the two 
antibodies, in layer V-VI of the somatosensory cortex (Fig. 4.10, A). The results obtained 
show a little variation, not statistically significant, in puncta density of the two GABAergic 
markers, in En2-/- and WT mice (Fig.4.10, A). Interestingly, these differences became 
significant once the PV/vGAT ratio is taken into account (Fig.4.10, B). 
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Fig.4.9 Synaptic density in En2-/- and WT mice, in somatosensory cortex. 
A) Representative images of PV and vGAT staining in cerebral cortex of WT mice. It has been 
considered layers V-VI in somatosensory cortex, in both the genotype. B) Images represent PV and 
vGAT staining in the cortex of En2-/- mice. In vGAT image, it is possible to observe a high magnification 
of a perisomatic vGAT ring. Scale bar: 200 µm. 
 
 
Fig.4.10. Distribution of synaptic puncta in the somatosensory cortex of En2 mutant and WT mice. 
A) The graphs show the spine density of two GABAergic marker, vGAT and PV, in En2-/- and WT mice. 
B) The PV/vGAT spine density ratio shows an increased expression in Parvabumin, compared to vGAT 
level, in En2-/- and WT mice. p-value: ***p < 0.001. 
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Dendritic spine analysis in the En2-/- hippocampus. 
Anatomical pathology of autism may involve abnormal spine generation or deficits in spine 
reorganization, elimination, and pruning (Hutsler & Zhang, 2010)(Gadad et al., 2013). The 
development of dendritic spines and synapses has been studied in several 
neuropathologies. Alterations in dendritic spines have been studied in a large number of 
brain disorders and may suggest the common cause for many neuropsychiatric 
syndromes, involving deficits in information processing (Penzes et al., 2011). Some animal 
models resemble these conditions: in fragile-X syndrome there is an abnormal abundance 
of long, thin protrusions and an increased spine density that apparently persists throughout 
life (Irwin et al., 2001)(Fiala et al.,2002). FMR1 KO mice exhibit elevated cortical spine 
densities, similar to those observed in autism, therefore, an overabundance of immature 
dendritic spines in cortical pyramidal neurons (Grossman et al., 2010)(Portera-Cailliau, 
2012)(Gadad et al., 2013). Mice deficient in MeCP2 also exhibit decreases in the number 
of functional, excitatory synapses (Chao et al.,2007)(Penzes et al., 2011); the Angelman 
syndrome mouse, which lacks the maternal UBE3A gene, displays altered spine density 
on hippocampal and cortical pyramidal neurons (Dindot et al., 2008)(Penzes et al., 2011). 
It has been postulated that GABA signaling plays an important role in regulating synapse 
development (Chattopadhyaya et al., 2007).  
We performed Golgi staining on young (p30) and adult (>5 months) En2-/- and WT mice. 
Brains were processed for Golgi staining and we collected images from basal and apical 
dendrites of CA1 pyramidal cell and from dendrites of granular cell layer in the dentate 
gyrus (described in materials and methods). In CA1 region, the apical dendrites occupy the 
stratum radiatum and stratum lacunosum molecolare, whereas the basal dendrites occupy 
the stratum oriens. The results showed an increased in spine density in the basal dendrites 
in hippocampus of adult En2-/- mice. In young mice (p30) the number of spines was 
reduced in apical and dentate gyrus, confirming that Engrailed could controls spinogenesis 
(Figs.4.11, A, B). 
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Fig.4.11. Spinogenesis in the hippocampus of En2-/- mice, at P30 and adult age. 
A) Representative images obtained after Golgi staining of mice hippocampi. Shown are apical and basal 
dendrites of WT and En2-/- adult mice. B) Quantification of spine density (per µm) in young and adult 
mice in WT and En2-/- mice. In B, *, p=0.0221 for ―apical‖ or p=0.0254 for ―DG‖ (t-test). In E, *, p=0.0219 
(t-test). Values are the mean +/- s.e.m. of spine densities measured from a total of 18-25 dendritic 
segments photographed from 2-3 mice per genotype and age group. Bar in A, 5µm.  
4.4 Brain derived neurotrophic factor and receptors 
BDNF RNA splicing variants in hippocampus and cerebral cortex of En2-/- mice. 
Brain-derived neurotrophic factor (BDNF) is a crucial factor for the postnatal development 
of forebrain GABAergic neurons (Huang et al.,2007)(Marín, 2012). BDNF, released from 
pyramidal axons, could signal to many GABAergic neurons and influence inhibitory 
innervation globally (Kohara et al. 2001) (Huang et al., 2007). 
Here we investigate whether altered BDNF expression may be related to the altered 
development of GABAergic interneurons described in En2-/- mice. We first performed a 
quantitative RT-PCR of the different BDNF mRNA isoforms in the cerebral cortex of En2-/- 
mice and WT controls. RT-PCR results demonstrated a remarkable reduction of different 
BDNF transcript variants in the cerebral cortex of En2-/- mice respect to controls, after 
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normalization to the mRNA of the housekeeping gene (ribosomal protein, L41) (Fig.4.12, 
A). Only ExonVII mRNA presented a comparable expression in WT and mutant mice. 
Conversely, in the En2-/- hippocampus, only ExonVII transcript variant was increased in 
En2-/- mice compared to WT, whereas the other BDNF mRNA level did not show any 
significant alteration (Fig.4.12, B)   
 
Fig. 4.12.Analysis of BDNF mRNA in brain regions of En2-/- mice and WT control: 
A) RT-PCR on BDNF transcript variants of cerebral cortex in En2-/- mice. There is a significant alteration 
in different BDNF transcript variants. B) Expression profile of different BDNF transcript variants in 
hippocampus of En2-/- mice compared to WT. The graph reveals an increase in ExonVII expression in 
mutant mice compared to WT. There is no significant alteration in the other mRNA variants between both 
the genotype. Values are expressed as each marker/L41 comparative quantitation ratios (mean ± s.e.m 
of 3 replicates, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, Student‘s t-test, WT vs. En2-/-).  
 
In situ hybridization of BDNF mRNA levels in different brain regions. 
In this study we analyzed the distribution of BDNF splice variants, in particular BDNF I, II, 
VI, and IXa, using cDNA probes. We verified the distribution of BDNF mRNAs in adult WT 
and mutant mice. Exon I-containing BDNF mRNA is expressed in the whole hippocampus 
and in detail, in the CA1, CA2, CA3 and granule cell layer of the dentate gyrus (DG) 
(Fig.4.13, A). Exon II BDNF splice variants [which include exon IIB and exon IIC] seems to 
be expressed with the same intensity in mutant and WT mice (Fig.4.13, B). Their 
expression remains strictly somatic: an observation in hippocampus areas supports a 
somatic localization of this transcript in both exon I and II transcripts, which were 
constitutively expressed in all principal hippocampal neurons. All cortical layers present a 
homogenous distribution of BDNF variants, without any difference between En2-/- and WT 
mice. These analyses demonstrate that there is no significant difference in the spatial 
expression of the different BDNF variants (BDNF I, II) in En2-/- brains. In the cerebellum, 
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the ISH show a reduction in the Purkinje cells in En2-/- mice, however any significant 
change in the spatial distribution of BDNF variants has been observed (Fig.4.13).   
 
 
Fig.4.13 In situ hybridization (ISH) of BDNF varinats in En2-/- and WT mice. 
A) B) Localization of exon I and II (IIB and IIC) BDNF splice variants. Images shown are representative 
sagittal sections of hippocampus, cerebral cortex and cerebellum of En2-/- mice compared to WT. Scale 
bar: 500 µm. 
 
We investigated also the subcellular distribution of Exon VI  and Exon IXa BDNF in En2-/- 
mice compared to controls. These BDNF variants are constitutively expressed in the entire 
hippocampus, in cerebral cortex and cerebellum of En2-/- mice and WT controls. As 
compared to Exon I and II, BDNF Exon IXa mRNA showed a similar expresion pattern in 
the En2-/- brain, with no detectable differences respect to WT mice (Fig.4.14). Exon VI 
mRNA instead showed a different profile (Fig.4.14, A). According to RT-qPCR data, BDNF 
Exon VI mRNA was  downregulated in the En2-/- cerebral cortex compared to WT. 
Contrary to what detected by RT-qPCR, down-regulation of BDNF Exon VI mRNA was  
also detected in the En2-/- hippocampus and cerebellum (Fig.4.14, B). 
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Fig.4.14 In situ hybridization (ISH) of BDNF varinats in En2-/- and WT mice 
Localization of exon VI and IXa BDNF splice variants. 
A) B) Images shown are representative sagittal sections of hippocampus, cerebral cortex and cerebellum 
of En2-/-mice compared to WT. Scale bar: 500 µm. 
BDNF protein isoforms in hippocampus and cerebral cortex of En2-/- mice: 
Yan and colleagues presented consistent results of subcellular localization of BDNF in the 
rat brain, confirming the idea that this neurotrophic factor has an important role in the CNS 
(Yan et al., 1997). They described in detail, by immunohistochemical analyses, that BDNF 
is expressed in the hippocampus, claustrum, basolateral amygdala and neocortex of adult 
rat brains (Yan et al., 1997). Following previous studies, we decided to performed 
immunohistochemical technique, in order to verify the BDNF protein expression in En2-/- 
mice and WT controls. 
The results presented here reveal a widespread localization of BDNF protein throughout 
the cerebral cortex and hippocampus areas, in both En2 mutant and WT mice.  The level 
of BDNF proteins seems to be comparable in both genotypes: a heavy staining may be 
observed in the CA1, CA2, CA3 and dentate gyrus regions. An intense staining is present 
also at the level of the cerebral cortex (Fig.4.15).    
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Fig.4.15. BDNF protein expression in En2-/- mice compared to WT. 
A) B) Representative immunofluorescence images of BDNF immunostaining. These are coronal sections 
of hippocampus and cerebral cortex, in En2-/- mice and WT controls. There is no significant difference in 
the BDNF protein expression in both the genotype. Scale bar 200um. 
Quantification of BDNF protein isoforms in hippocampus: 
In order to elucidate whether there is an alteration in BDNF protein expression in En2 
mutant mice, we quantified the different BDNF isoforms in two brain regions, in which we 
observed an alteration in BDNF mRNA level. Previous results reveal an alteration in BDNF 
ExonVII expression in hippocampus and a significant decrease in different BDNF splice 
variants in cerebral cortex of En2 mutant mice, compared to WT.  
We therefore analyzed, by western blotting analysis, the expression of truncated-, pro-, 
and mature BDNF isoforms in hippocampus and cerebral cortex of En2-/- mice, compared 
to WT. The antibody used detected three immunoreactive bands: the 35-kDa band 
corresponds to the pro-BDNF molecular weight (pro-BDNF), the 28-kDa band corresponds 
to truncated form of pro-BDNF and with 14-kDa band was identified the mature 
BDNF isoform. Band densitometry allowed us to measure the relative percentage of the 
three isoforms compared to total BDNF, expressed as the ratio of the densitometric value 
of a given BDNF isoform and the sum of the densitometric values of all isoforms (pro-
BDNF + truncated-BDNF + mature-BDNF)(Fig.4.16,A). The isoforms relative percentage of 
the two genotypes was then compared. Our results demonstrate a low expression of 
truncated BDNF isoform (Fig.4.16, A), revealing a significant decrease in the truncated 
BDNF/total BDNF ratio in mutant mice versus controls. The ratio of mat-BDNF and pro-
BDNF/total BDNF was comparable between WT and En2-/- mice (Fig.4.16, B).  
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Fig.4.16 Quantification of BDNF in En2-/- and control samples by Western blotting: 
A) Representative western blot of BDNF isoforms. Housekeeping is representing with B-Tubulin bands, 
in the upper part of the membrane. B) Western Blot graph indicated a significant down-regulation of pro-
BDNF isoform, whereas, the other isoforms remain unaltered. For each sample, the pixel value of each 
BDNF isoform was expressed as a ratio to total BDNF pixel values, where total BDNF is the sum of pro-
BDNF + 28-kDa truncated BDNF + mature BDNF. P value: * p < 0.05, 2-taile d t test. Bars represent 
mean ± SE. (sample n=4).  
 
We next extended our quantification analysis to this brain area and investigated the BDNF 
protein expression in cerebral cortex of En2-/- mice compared to WT controls. Western 
blotting revealed no significant difference in the BDNF isoforms in both En2-/- and control 
group regions. Mutant mice present a significant up-regulation of pro-BDNF isoform. No 
significant alteration was observed for the expression of truncated and mature BDNF 
isoforms in En2-/- versus WT mice. (Fig.4.17, B). 
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Fig.4.17 Quantification of BDNF in En2-/- and control samples by Western blotting in cerebral cortex: 
A) Representative western blotting showing the relative expression of BDNF isoform, pro-, truncated and 
mature BDNF isoforms. B) Graph representing relative percentage of pro-BDNF, truncated or mature 
BDNF with respect to the total amount of serum BDNF (total BDNF is calculated as the sum of the 
densitometric values of the three BDNF isoforms in each sample. Bars represent mean ± SE (sample 
n=3). P value *p < 0.05, 2-tailed t test. 
4.4.1 P75 and TrkB receptors expression 
 
In order to complete the BDNF expression analysis we extended our study to BDNF 
receptors. We performed quantitative real time PCR experiments, which showed a 
significant downregulation of p75 receptor in the hippocampus and cerebral cortex of En2-
/- mice, compared to controls. The TrkB expression is unchanged, with the only exception 
in TrkB-full length, in the hippocampus of En2-/- mice versus WT groups (Fig.4.18, B). 
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Fig.4.18. mRNA expression of BDNF receptors: 
A) Quantitative RT-PCR analysis in cerebral cortex of BDNF receptors markers: mRNA expression 
reveals a down-regulation of p75 marker in En2-/- mice. TrkB mRNA levels are comparable in both 
genotypes B) The full length of TrkB results increased in mutant mice, whereas, the truncated isoforms 
have no significant difference in En2-/- and control mice.  Reduced p75 expressions in hippocampus of 
En2-/- mice compared to WT. Values are plotted as the mean ± s.e.m of 3 replicates from pools of 3 
animals per genotype. In all graphs, asterisks indicate statistical significance (*p < 0.05, ***p < 0.001, 
Student's t-test, WT vs. En2-/-) 
 
Following these results, we decided to investigate the expression of the high-affinity BDNF 
receptor, TrkB, using western blotting experiment. The results obtained demonstrate an 
upregulation of TrkB receptor in the hippocampus of En2-/- mice, compared to control 
group (Fig.4.19).  
 
 
 
Fig.4.19. Protein expression of TrkB receptor in hippocampus of En2-/- mice: 
A) Immunoblot on PVDF membrane showing TrkB expression: GAPDH is included as control. B) 
Western blotting analysis reveals an increase of TrkB level in En2-/- mice compared to wild types (n=3 
per group). Unpaired t-test: En2-/- vs WT controls, p-value * p < 0.05. (Sample n=3 per genotype). 
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4.5 BDNF treatment in En2-/- hippocampal cell cultures  
BDNF is known to be required for proper development and survival of dopaminergic, 
GABAergic, cholinergic, and serotonergic neurons. Recent study demonstrated that BDNF 
promotes the formation of GABAergic synapses in hippocampal and cortical 
culture and can potentially adjust the number and strength of GABAergic synapses onto 
targeted glutamatergic cells (Huang et al., 2007). BDNF is produced mainly by cortical 
glutamatergic cells and its signaling is activity-dependent. Indeed, previous 
immunohistochemical analyses revealed that En2 is expressed also in pyramidal neurons), 
suggesting that En2 ablation could affect BDNF expression in glutamatergic neurons. The 
decrease expression in different BDNF splicing variants in En2 mutant mice support this 
hypothesis, suggesting that alteration of BDNF might play a role in the aberrant GABAergic 
interneuron development observed in the En2-/- mice. For this purpose, we analyzed the 
effect of BDNF treatment in postnatal hippocampal cell cultures.  
Morphology of primary hippocampal neuron in En2-/- mice vs WT. 
In order to establish a mature hippocampal cell culture, we used long-term hippocampal 
cultured neurons (2 weeks), which tend to have synapse maturity (Fig.4.20, A). Neurons in 
culture have distinct stages of development, starting with extension of lamellopodia, 
followed by axon and dendrite specification and extension and synapse formation and 
maturation (Beaudoin et al., 2012). The peak of dendritic growth and synapse formation 
occurs during the second and third weeks in culture, with dendritic spines first appearing at 
about 2 weeks in culture. At this stage, hippocampal cultures have formed such a dense 
network.  
 
Fig.4.20 Representative images of cultured hippocampal neurons. 
A) Images of neurons at different stages during culture—DIV 7 and DIV14. Note how neuronal 
morphology and arborization develop over time. Scale bar 25µm.  
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Primary hippocampal neurons were cultured in the continuous presence of BDNF protein 
in the medium (20ng/ml). To test how BDNF acts at dendritic level and to determine the 
possible alterations in spine density, we co-stained neurons with anti-vGAT (vescicular 
GABA transporter), vGlut-2 (vescicular Glutamate transporter-2) and anti-MAP2 
antibodies. MAP2 is known to label the somatodendritic contour of neurons, but not the 
presynaptic compartments such as dendritic spines or postsynaptic densities (Bernhardt & 
Matus, 1984), whereas vGAT is highly concentrated in the nerve endings of GABAergic 
neurons in the brain. 
We performed a confocal analysis of cultured hippocampal neurons labeled anti-vGlut-2 
(vesicular glutamate transporter) and anti-vGAT (inhibitory vesicular transporter). In 
particular, we stained for vGAT, vGlut2 and MAP2, acquiring at high-resolution (63X) with 
confocal microscope (Fig.4.21) (Fig.4.22). Cultured neurons extend neurites that have 
characteristic morphologies (Fig. 4.21, a,b,c) and express appropriate dendritic (MAP2) 
marker. They possess excitatory synapses, as indicated by staining for vGlut2 (excitatory 
presynaptic marker) and inhibitory synapses, as indicated by vGAT (inhibithory presynaptic 
marker) as previously reported (Yamada et al., 2002). We performed immunostaining on 
hippocampal neurons treated and untreated (control cells) with BDNF protein after two 
weeks in culture. On these cells, we studied spine density, visualizing the typical ―spot‖ 
representing the synaptic puncta, stained with vGAT or vGlut2 antibodies, and the 
―fragments‖ representing the dendrites length. Synaptic density was assessed using 
Columbus software that allows the determination of the number of synaptic puncta on 
dendrites length.  
 
No significant differences were observed between control and BDNF-treated cultured 
neurons, in En2-/- and WT mice. All cell cultures present a normal growth efficiency and 
adherence to the slide. Observing the MAP2 staining, it seems that BDNF treatment leads 
to a decrease in cell density, in the level of branching and the number of connections 
between neurons. The connections present in the treated cells, although less numerous, 
appear less branched. This effect can be seen looking at the pictures with MAP2 staining 
(Figs.4.21 c, d,) (Figs.4.22 c, d). Conversely, in the control is observed a high degree of 
branching, with a higher number of connections (Figs.4.21 a, b) (Fig.4.22 a, b). The puncta 
staining characterizes both the GABAergic and glutamatergic marker, but vGAT has a 
lower signal compared to vGlut2.  In En2-/- treated neurons the vGAT and MAP2 staining 
seems to be damage, suggesting a possible suffering of neurons after the treatment.  
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Fig.4.21. vGAT staining of primary postnatal hippocampal cell culture. 
a) a’) a”) Images show MAP2 and vGAT staining in WT hippocampal neurons at DIV14. b) b’) b”) 
Representative images of postnatal cell culture neurons of En2 mutant mice. It is possible to observe a 
vGAT staining (red) and MAP2 expression (green). c) c’) c”) BDNF treatment in WT hippocampal 
neurons, stained at DIV14 with MAP2 (green) and vGAT (red) antibodies. d) d’) d”) Images show En2-/- 
cell culture neurons treated with BDNF. Immunofluorescence performed using MAP2 and vGAT staining. 
Scale bar: 50 µm. 
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Fig.4.22. vGlut2 staining of primary postnatal hippocampal cell culture. 
a) a’) a”) Images show MAP2 and vGlut2 staining in WT hippocampal neurons at DIV14. b) b’) b”) 
Representative images of postnatal cell culture neurons of En2 mutant mice. It is possible to observe a 
vGlut2 staining (green) and MAP2 expression (red). c) c’) c”) BDNF treatment in WT hippocampal 
neurons, stained at DIV14 with MAP2 (green) and vGlut2 (red) antibodies. d) d’) d”) Images show En2-/- 
cell culture neurons treated with BDNF. Immunofluorescence performed using MAP2 (red) and vGLut2 
(green) staining. Scale bar: 50µm. 
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GABAergic synapse analysis in postnatal hippocampal neurons. 
We used double immunostainings for MAP2 and vGAT to quantitatively analyze 
GABAergic synapse in WT and En2-/- hippocampal cultures treated and untreated with 
BDNF. Double stainingg were analyzed by confocal imaging. The resolution obtained with 
the confocal microscope allowed the study of individual synapses. However, Z stack 
images with a step interval of 0.10 μm supplemented each XY image for accurate synapse 
quantification. The results obtained from postnatal hippocampal cell cultures at DIV14 
exhibited a significant difference between WT and En2-/- untreated cultures (no BDNF 
treatment) (Fig.4.23). A significantly decreased number of vGAT-positive puncta was 
detected between BDNF-treated and BDNF-untreated WT neurons. These results showed 
a significant difference in spine density between the genotype. 
 
 
 
Fig.4.23 Statistical analyses of vGAT synapse density. 
The graph shows GABAergic synapse density in En2-/- and WT hippocampal cultures, evaluated by 
vGAT staining. ***p<0.001, two-way ANOVA followed by Tukey's multiple comparisons test. 
 
We also investigated the effect of BDNF on glutamatergic synapse density in WT and En2-
/- hippocampal cultures using immunostaining for the glutamatergic marker vGlut2. The 
analyses revealed a significant decrease of vGlut2 puncta in En2-/- cultures in the absence 
of BDNF treatment. BDNF treatment significantly decreased vGlut2 puncta in WT neurons, 
while increasing the number of vGlut2 synapses in En2-/- hippocampal neurons (Fig. 
4.24). 
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Fig.4.24 Statistical analyses of vGlut2 synapse density. 
The graph shows glutamatergic synapse density in En2-/- and WT hippocampal cultures, evaluated by 
vGlut2 staining. ***p<0.001,****p<0.0001,  two-way ANOVA followed by Tukey's multiple comparisons 
test. 
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5. DISCUSSION 
5.1 Brief summary of results 
In this study, we showed that GABAergic interneurons are partially lost in the cerebral 
cortex and hippocampus of adult En2-/- mice, a well-recognized model of ASD. 
Interneuron loss was accompanied by altered spine density and increased number of PV-
positive puncta in the En2-/- forebrain. Considering the crucial role of BDNF in forebrain 
GABAergic interneuron development, we sought to determine whether interneuron loss in 
En2-/- forebrain might be related to altered expression of BDNF and its signaling 
receptors. Quantitative RT-PCR experiments revealed a markedly decreased expression 
of various splicing variants of BDNF mRNA in the cerebral cortex but not hippocampus of 
adult En2-/- mice, as compared to WT controls. Immunoblot analyses instead revealed 
increased levels of mature BDNF, and reduced levels of truncated- and pro-BDNF 
isoforms in the hippocampus of En2-/-, as compared to WT controls. These variations 
were accompanied by reduced levels of p75 and increased levels of TrkB receptors in the 
En2-/- forebrain. We next used primary cultures of hippocampal neurons from WT and 
En2-/- mice to investigate the effect of BDNF on GABAergic and glutamatergic neuron 
connectivity. Preliminary results indicate that BDNF is able to increase the number of 
GABAergic and glutamatergic synaptic contacts in En2-/- hippocampal neurons. Our 
results suggest a beneficial role of BDNF in rescuing synaptic defects of GABAergic and 
glutamatergic neurons in En2-/- mice. 
5.2 En2, GABAergic interneurons, and postnatal forebrain development 
Loss of forebrain GABAergic interneurons in En2-/- mice.  
Previous studies from our laboratory showed that En2 mRNA is expressed in the adult 
mouse hippocampus and cerebral cortex, suggesting that En2 may also function in these 
brain areas (Tripathi et al., 2009). Since then, other studies confirmed that En2 transcripts 
are expressed at low but significant levels in several telencephalic structures, such as the 
cerebral cortex, the hippocampus, and other areas of the limbic system (i.e. the amygdala) 
(Brielmaier et al., 2012) confirming and expanding our mRNA expression analysis. mRNA 
expression does not however indicate the presence of a functional protein; we therefore 
expanded this data demonstrating the presence of both Engrailed proteins in cortical and 
hippocampal GABAergic interneurons and reported alterations in the development and 
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maintenance of GABAergic interneurons also in forebrain areas in the absence of En2 
(see Results, Fig.4.1). We investigated the expression of both Engrailed proteins, 
describing their expression in a subsets of PV- and CALB-expressing GABAergic 
interneurons in the postnatal mouse hippocampus and somatosensory cortex. In 
accordance, En2 ablation results in a partial loss of PV, NPY and SOM (but not CALB) 
interneurons in the somatosensory cortex and in the hippocampus, without affecting the 
total number of GAD-expressing interneurons (see Results, Fig.4.3). In the visual cortex, 
instead, En2-/- mice show a decreased number of SOM and NPY interneurons, but not of 
PV interneurons, without significant alterations in the total number of interneurons, as 
measured by GAD-espression. In both somatosensory and visual cortex the pattern of 
GABAergic interneuron reduction appears layer-specific, being confined for superficial 
layers in the case of SOM interneurons. The PV-positive cell population seems also less 
affected in the visual cortex as compared to the somatosensory cortex, suggesting that 
different sensory cortices display a distinct profile of interneuron maturation in En2-/- mice. 
Indeed, the somatosensory cortex has a greater number of PV+ interneurons as compared 
to the visual cortex (Tanahira et al., 2009). Overall, these data indicate that 
the En2 mutation has a very selective, region-specific effect on different subpopulations of 
cortical GABAergic interneurons. Previous studies showed that loss of En2 markedly 
reduces neurogenesis in posterior brain areas, including development of inhibitory neurons 
in the cerebellum. Reduction in number and a delay in maturation of CALB-expressing 
Purkinjie neurons has been described In the cerebellum of En2-/- mice (Kuemerle  et 
al.,1997)(Kuemerle et al.,2007) (Sudarov & Joyner, 2007), suggesting that the En2 gene 
may have a direct effect on the development of this inhibitory neurons. 
As for the expression of the GABAergic interneurons markers at mRNA level, 
discordances have arisen with the cell counting experiments. PV mRNA levels and PV 
interneurons were both reduced in the somatosensory cortex of En2 mutants; conversely, 
a loss of NPY and SOM neurons was not paralleled by lower mRNA expression levels. 
This discordance could be due to up-regulation of NPY and SOM mRNAs in the remaining 
interneurons of the En2-/- somatosensory cortex to compensate for the loss of their input. 
It would be interesting to explore this hypothesis analyzing the SOM and NPY innervation 
on principal neurons. The downregulation of CALB mRNA in the absence of a reduced 
number of CALB-positive neurons in the En2-/- cortex might be related to hyperexcitability 
(Sonnenberg et al., 1991). It is important to point out that En2-/- mice do display 
hippocampal and cortical hyperexcitability, as determined by increased susceptibility to 
KA-induced seizures (Tripathi et al., 2009). This study also demonstrated that the 
expression of En2 mRNA in the adult hippocampus was downregulated by seizure activity, 
indicating that En2 may be also involved in the functioning of adult brain areas and in their 
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response to seizures (Tripathi et al., 2009). Recent transcriptome study, from our 
laboratory, performed in the En2-/- hippocampus, supports this hypothesis. Bioinformatic 
analysis of enriched gene ontology terms and functional pathways in the differentially 
expressed genes revealed that ablation of En2 induces a prevalence of terms and 
pathways related to seizure, altered synaptic transmission, as well as neuronal activities 
and calcium mediated signal (Sgadò et al., 2013).  
 
Overall, these findings are in line with the hypothesis that structural and functional 
abnormalities of GABAergic interneurons might represent the anatomical substrate of an 
unbalanced excitation/inhibition ratio in the cerebral cortex and other brain areas, which 
has been postulated to occur in the autistic brain (Rubenstein and Merzenich, 2003). Other 
studies suggested this hypothesis. Gogolla and colleagues confirmed, by a meta-analysis 
study, a reduction of PV-positive cells in the neocortex of ASD mouse models as 
compared to control mice (Gogolla et al., 2009) (Medrihan et al., 2008). Moreover, a 
marked loss of PV-expressing interneurons has been detected in the somatosensory 
cortex of Fmrp1 and Nlgn3 mutants (Durand et al., 2012). 
Altered or delayed development of GABAergic inhibition has been proposed as a 
pathogenic mechanism of multiple neurodevelopmental disorders, including ASD (Di 
Cristo, 2007). Lawrence and colleagues showed an abnormal density of Calretinin-, CALB- 
and PV-immunoreactive interneurons in the post-mortem studies in hippocampus of ASD 
patients, compared to control samples (Lawrence et al., 2010). They proposed that 
GABAergic interneurons dysfunction may have a crucial role in the brains of individual with 
autism (Lawrence et al., 2010). A GABAergic signaling dysfunction has been investigated 
in ASD patients in several instances: a reduction in GAD65/67 proteins levels has been 
shown in post-mortem tissues in the cerebellum and cerebral cortex from autistic patients 
(Fatemi et al., 2002)(Pizzarelli & Cherubini, 2011) (Chattopadhyaya et al., 2012).  
Delay in visual cortex circuit development.  
To analyze possible alterations of GABAergic interneurons in the visual cortex of En2-/- 
mice and its possible impact on cortical function we investigated, in collaboration with the 
CNR Institute of Neuroscience, the functional features of the mouse visual system to 
elucidate the relationship between GABAergic dysfunction and maturation of cortical 
function in En2-/- mice (Allegra et al., 2014). In parallel with the a lower number of SOM- 
and NPY- (but not PV-) positive cells detected in the adult visual cortex of En2-/- mice, we 
also found a developmental decrease of SOM- and PV- cells in the visual cortex of En2-/- 
as well as in WT mice, though less pronounced than that observed in En2-/- animals 
(Allegra et al. 2014). The visual cortex has been used as a model system to test the 
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physiological consequences of an altered development of the GABAergic system. As an 
assay of the potential for plasticity, many groups employed the paradigm of monocular 
deprivation. The anatomical abnormalities, in the visual cortex, were accompanied by a 
significant increase of binocularity in juvenile and adult En2-/- mice, and by the inability to 
respond to a brief monocular deprivation performed during the critical period and in 
adulthood (Allegra et al., 2014). In addition, the electrophysiological analysis demonstrated 
that several basic physiological properties (visual acuity, latency and amplitude of the 
visual response, receptive field size, spontaneous discharge) were within the normal range 
in both juvenile and adult En2-/- animals (Allegra et al., 2014). Thus, lack of En2 
selectively affects balance of eye-specific drive in the primary visual cortex while leaving 
the development of other functional properties unaffected. The enhanced binocularity of 
En2-/- mice is likely of cortical origin and not secondary to alterations in retinogeniculate 
afferents, as a normal segregation of eye-specific inputs was found in the dLGN (Allegra et 
al., 2014). 
Moreover, application of a brief period of monocular occlusion in juvenile mice lacking En2 
failed to produce an ocular dominance shift while it was extremely effective in aged-
matched WT animals. Response to monocular deprivation was also not detectable in adult 
En2-/- mice. Furthermore electrophysiological recordings in the visual cortex ipsilateral to 
the deprivation were able to demonstrate a genuine deficit in plasticity. Thus, lack of En2 
impairs activity-dependent modifications at the peak of the ―normal‖ critical period. 
Previous studies have examined the role of GABAergic inhibition in the control of visual 
plasticity, showing that the proper maturation of the GABAergic system is a crucial 
determinant of cortical plasticity during postnatal development (Hensch et al., 1998). 
Susceptibility to monocular deprivation has recently been used to assess plasticity of 
cortical networks in models of mental retardation and ASD such as Fmr1 (Dölen et al., 
2007) and MeCP2 (Tropea et al., 2009b) mutant mice, which are known to present 
anatomical and functional deficits of cortical GABAergic interneurons (Centonze et al., 
2008) (Chao et al., 2010).  
Developmental defects in GABAergic interneurons.  
A set of preliminary data, obtained from our laboratory, demonstrated a significant 
reduction in SOM- and PV- positive interneurons at different stages of postnatal 
development (P10, P30): the considered areas were the somatosensory cortex and the 
hippocampus of En2-/- mice and WT. These results, obtained at early postnatal stages, 
support our theory that En2 might be involved in the development and migration of 
interneurons subpopulations. This phenomenon could be explained in terms of distribution: 
the maturation and stabilization of the total number of these interneurons occurs at around 
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P30-P40, therefore, it may still be subject to modification at P30 age, when the 
interneurons are not fully mature and stable (Huang et al., 1999). This suggests that the 
En2 gene, delaying the maturation of these cells, may also be involved in their late 
maturation. We hypothesize that the loss of En2 may have a specific effect, direct or 
indirect, in the postnatal maturation of GABAergic cells. This defect might indicate an 
immature and unbalanced connectivity in the cortex that underlies the complex behavioral 
phenotype of En2-/- mice, a mouse model that mimics the autistic phenotype. GABAergic 
interneurons are crucial for activity-dependent remodeling of cortical circuits; alterations of 
these cells during development could produce non cell-autonomous changes and alter 
brain connectivity in general. 
 
The next step will be to understand how and at which stage of development En2 protein is 
crucial for the correct development of these classes of interneurons. To this purpose, we 
could make use of En2 conditional mutant mice with specific ablation of En2 in GABAergic 
interneurons or glutamatergic neurons. These conditional mice could elucidate other 
aspects on the origin of GABAergic alteration observed in the En2-/- forebrain. It might be 
interesting to understand if these interneurons defects are due to altered specification, 
migration or during the differentiation of these cells populations. The generation of 
conditional mutants specifically lacking En2 in forebrain interneurons is currently ongoing 
in our laboratory. 
5.3 Synaptic development in the En2-/- forebrain 
Dendritic spine density in En2-/- mice.  
Several genome-wide association studies have identified polymorphic variants in genes 
encoding synaptic proteins as important determinants of the risk of developing ASD (van 
Spronsen & Hoogenraad, 2010). Recent transcriptome profiles from three different brain 
regions (frontal cortex, temporal cortex and cerebellum) have demonstrated a 
downregulation of genes involved in synaptic function and vesicular transport in ASD 
patients (Voineagu et al., 2011). These data have been confirmed also in our mouse 
model, using a transcriptome analysis (Sgadò et al., 2013). In particular, our bioinformatics 
analysis of the differentially expressed genes in the hippocampus of En2-/- mice found 
significant enrichment for terms related to seizure and altered synaptic transmission 
(Sgadò et al., 2013). These data lead us to hypothesize defects in synaptogenesis and 
spine density alterations in our En2 mouse model. To this purpose, Golgi staining was 
performed on the hippocampus of En2-/- mice compared to WT, in juvenile and adult mice. 
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En2-/- mice displayed a significant decrease in spine density on apical dendrites of CA1 
region and on dendrites of granule cells in DG, at p30 age. We found also an increased 
spine density in the basal dendrites of CA1 region, in adult age. These results might be 
consistent with the idea that En2 promotes spinogenesis. In collaboration with the 
―Laboratoire de dynamique membranaire et maladies neurologiques‖ in Paris (Prof. Olivier 
Stettler), we investigated the role of Engrailed in cell culture medium during hippocampal 
cell differentiation. Engrailed protein treatment in culture produces an increase of dendritic 
complexity and an excess of spinogenesis, increasing immature and plastic spines. This 
data support the hypothesis that Engrailed genes may participate to the fine tuning of 
synaptic formation in the hippocampal network (Soltani et al., in preparation).  
Increased spinogenesis has been observed also in other ASD mouse models. In adult 
Fmr1 KO mice, Golgi staining in the cerebral cortex reported a higher density of cortical 
spines than in controls (Comery et al., 1997) (Dölen et al., 2007). This data has been 
recently contradicted, reporting a normal spine density in juvenile and adult Fmr1KO mice 
(Pan et al., 2010), arguing that this result could be due to a technical artifact of the Golgi 
method. However, in the hippocampal cultures of Fmr1 mutant mice have been reported to 
have a lower spine density (Braun & Segal, 2000), which would be in accord with what has 
been seen in our hippocampal cultures treated with Engrailed (Soltani et al., in 
preparation). We also observed an opposite result of the spine density between young and 
adult En2-/- mice. This discrepancy might be correlated to a high vitality of spine turnover 
in young animals, which is altered /arrested with the adult age, leading to an increase of 
immature spines. The immaturity of spine is correlated with the stabilization of the dendritic 
spines, which is independent of the spine density measured by Golgi and could be 
analyzed by other means (Portera-Cailliau, 2012).  Therefore, an increase spine density in 
the adult En2 mutant mice might suggest a compensatory mechanism, due to a possible 
aberrant morphology of spine in adult En2-/- mice.  
Following our recent experiments, the next goal will be to detect alterations in spine size 
and morphology, considering the importance of the dynamics of spine in the healthy brain. 
It could be significant to study the morphology of the spines, in order to understand in 
which way the instability of the spine influence the proper balance between stable and 
dynamic connections, this latter fundamental to define mature synapses (Portera-Cailliau, 
2012).  
Synaptic connectivity in En2-/- mice.  
Considering the potential effect of En2 on spine formation, we examined the possible role 
of En2 in synaptic formation and maturation, in our mouse model. We approached this 
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hypothesis analyzing the perisomatic innervation of GABAergic synapses in fixed tissue 
and evaluating the synaptic puncta in vitro.  
Given the importance of GABAergic function in the formation of synaptic circuits, reduced 
GABAergic inhibition and its link to synaptic development may be considered a recurrent 
pathophysiological mechanisms for ASD and for many other neurodevelopmental 
disorders (Hussman, 2001) (Bateup et al., 2013). Following previous analyses on the study 
of spine density in hippocampal area of En2-/- mice, we extended our research on the 
possible alteration of GABAergic synapse density in En2-/- mice and WT controls. The 
failure of spine to stabilize during development strongly suggests that En2-/- mice could 
have problems in maintaining a proper balance in the brain connectivity therefore failing to 
establish stable and/or dynamic connections in the brain.  
To study the interneurons synaptic connections on cortical principal pyramidal neurons, we 
crossed En2 mice with Gad1-EGFP (line G42) mice, selectively expressing enhanced 
green fluorescent protein (EGFP) in PV-positive basket interneurons and in putative 
presynaptic boutons (Chattopadhyaya et al., 2004). Previous studies showed a higher 
distribution of GFP-positive neurons in infragranular layers V and VI, in the visual cortex 
(Chattopadhyaya et al., 2004).  In our case however, the GFP transgene expression in the 
synaptic boutons was lower compared to the original strain, therefore the perisomatic 
innervation was analyzed using PV antibody. We anyway focused our attention on the 
synaptic connections that GABAergic interneurons generate with layer V-VI pyramidal 
neurons, where a higher concentration of transgene expression had been reported, using 
PV and vGAT antibody. The results show a small change, not statistically significant, in 
synapse density of the two GABAergic markers, in En2-/- mice compared to WT. By 
observing the trends of vGAT and PV in both the genotypes, we hypothesized an increase 
in PV interneurons expression and a decrease in vGAT number, to be further 
characterized. Interestingly, these differences became significant among genotypes once 
the PV/vGAT ratio was taken into account. This ratio measures the mean intensity of PV 
and vGAT staining, without considering the area of the cells included in the analysis. 
Indeed, we found an increase in the area of pyramidal cells in En2-/- mice compared to 
WT and this result affected, negatively, the trend of GABAergic synaptic markers 
expression. Whether the area difference represents a technical artifact or an actual effect 
of En2 on pyramidal neurons needs to be established. 
As a future perspective, we might consider extending our study to the visual cortex, where 
we observed developmental alterations in GABAergic interneurons, expanding the analysis 
to other layer of the somatosensory cortex, for examples, layer II-III and IV. 
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Synaptic density in hippocampal cell cultures.  
To further characterize the synaptic density phenotype in our model we examined synaptic 
formation in cell cultures. We performed double fluorescent immunostaining of vGAT-
MAP2 and vGlut-MAP2 antibodies to be able to analyze the dendritic development in 
culture. The results obtained from hippocampal cell culture after 14 days in culture showed 
a significant alteration between WT and En2-/- neurons. We observed a significant 
increase number of vGAT dendritic puncta in En2-/- cultures compared to WT. This is in 
agreement with previous RT-qPCR results performed on visual cortex of En2-/- mice. 
Indeed, we have shown an increase mRNA expression in visual cortex of En2-/- mice, in 
vivo, but we have not analyzed the spine density (perisomatic puncta) in this area. 
Furthermore, our in vitro analyses revealed an increase protein expression in this 
GABAergic marker only on the dendritic tree, excluding the soma.  Our aim was also to 
consider the glutamatergic spine density in the cultured neurons, using vGlut2. Also in this 
case we found a significant decrease of dendritic glutamatergic puncta, confirming our in 
vivo analyses of vGlut mRNA level in the visual cortex of En2-/- mice. This data suggest an 
altered maturation of synaptic connection and dendritic development in En2-/- mice. 
 
The sequential development of GABA- and glutamate-mediated connections is 
independent on the arrival of afferent dendritic inputs but is related to the degree of 
maturation of the targeted cells (i.e. dendritic length, somatic size) (Tyzio et al., 1999). 
Hence, GABAergic synapses development requires the presence of small apical dendrites 
in stratum radiatum of the hippocampus. Our Golgi analysis indicated a decreased spine 
density in the stratum radiatum of the CA1 of young En2-/- mice that could lead to a loss of 
GABAergic synapses and GABAergic neurons. We might also hypothesize that the loss of 
GABAergic input induces the increased number of spine in CA1 hippocampal region in the 
adult, contributing to establish immature synaptic circuits. 
5.4 BDNF expression in the En2-/- forebrain 
Expression of different BDNF splicing variants in En2 brain.   
Previous studies showed that some BDNF transcript variants are implicated in cell survival, 
while other are involved in the regulation of dendritogenesis and spinogenesis (Xu et al., 
2000)(Berghuis et al., 2006). BDNF, released from pyramidal axons, could signal to 
GABAergic neurons and influence inhibitory innervation globally (Kohara et al., 2001) 
(Huang et al.,2007). In our study, we investigated whether altered BDNF expression might 
be related to the altered development and synaptic connectivity of GABAergic interneurons 
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detected in the En2-/- forebrain. According to previous studies, we focused our attention 
on BDNF mRNA splice variants, using in situ hybridization and RT-qPCR techniques. 
Firstly, in order to understand the expression of BDNF splice variants in the hippocampus 
and cerebral cortex of En2-/- mouse model, we analyzed the mRNA level by RT-qPCR of 
different splicing variants (in detail, Exon I, II, IV, VI, VII, IXa). RT-PCR results 
demonstrated a significant reduction of different BDNF transcript variants in cerebral cortex 
of En2-/- mice: all BDNF splice variants showed an important decrease in En2-/- mice 
compared to the control (see Results, Fig. 4.15). This is in agreement with previous 
studies, which showed the decrease level of BDNF mRNA in individuals with Alzheimer 
disease (Phillips et al., 1991) and Huntington disease (HD) (Ferrer et al., 2000) (Zuccato et 
al., 2005). In the cerebral cortex of HD mouse model, a decrease in mRNA level from early 
pre-symptomatic stages was reported (Zuccato et al., 2005). A quite widespread reduction 
in cortical BDNF mRNA has been observed also in schizophrenia (Ray et al., 2014). Thus, 
BDNF splice variants decrease may underlie a general decrease in cortical BDNF 
expression that may participate to the defects observed in GABAergic interneurons in our 
model. 
Analyzing the hippocampus of En2-/- mice, we instead found a significant increase in Exon 
VII transcripts variant, in the hippocampus of En2-/- mice, compared to WT, while no other 
BDNF splice variant showed substantial alteration. This might be in agreement with 
previous study on autistic patients, which showed no significant difference in BDNF mRNA 
levels in the fusiform gyrus of control and autism samples (Garcia et al., 2012). Preliminary 
results obtained by specific laser microdissection analyses (LMD) from our laboratory 
confirmed the increased of BDNF Exon VII transcript variants in the hippocampus of En2-/- 
mice compared to WT. We collected somatic and dendritic areas of the hippocampal 
region and demonstrated an increase of BDNF Exon VII expression in somatic CA3 area. 
LMD revealed a general trend of BDNF somatic expression compared to dendritic level, in 
the hippocampus of En2-/- mice.  
Performing in situ hybridization analyses, we demonstrated a widespread level of the 
mRNA expression in the hippocampus, cerebral cortex and cerebellum of our mouse 
model and WT control, at adult age. These data confirmed that a large amount of BDNF 
mRNA has been found in these three important brain regions, without particular difference 
in the distribution between the genotype. In situ hybridization confirmed the decreased 
expression in Exon VI BDNF variants in the cerebral cortex. Contrary to what detected by 
RT-qPCR, down-regulation of BDNF Exon VI mRNA by in situ hybridization was also 
detected in the En2-/- hippocampus and cerebellum.  
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Expression of different BDNF isoform in En2-/- brain.  
The presence of BDNF mRNA may be taken as an indication of the distribution of the 
BDNF protein. However, the expression of mRNA does not reflect the rate of protein 
synthesized because of the post-translational modifications. In the present study, we also 
examined BDNF protein expression, using Western blotting and immunohistochemistry 
analyses, in the cerebral cortex and hippocampus of En2-/- and WT mice. 
Immunofluorescence experiments revealed that there is a widespread distribution of BDNF 
protein in the hippocampus and cerebral cortex of En2-/- mice. We next used western blot 
to investigate the presence of the different BDNF isoforms in our En2 mouse model 
(Marcinkiewicz et al., 1998) (Michalski & Fahnestock, 2003). Western blot detection 
revealed a decreased expression in pro-BDNF signal in hippocampus of En2 mutant mice 
compared to WT. Conversely, we demonstrated a marked increase of pro-BDNF level and 
a decrease of truncated isoform in cerebral cortex of En2-/- mice compared to WT. The 
total number of the three BDNF isoforms did not change in our mouse model compared to 
WT (data not shown). Therefore, the balance among all three BDNF isoforms is very 
important: the increased pro-BDNF and reduced truncated BDNF isoform, in the cerebral 
cortex of En2 mutant mice, suggests that this isoform may be responsible for reduced 
neuronal differentiation and dendritic spines. Indeed, previous analyses performed on 
autistic patients (Pang et al., 2004)(Teng et al., 2005) (Garcia et al., 2012) demonstrate an 
alteration in pro-BDNF isoform, suggesting that this might lead to alteration in synaptic 
connectivity at neurotransmitter levels in autistic patients (Garcia et al., 2012). Translation 
or mRNA stability could not account for these differences in BDNF isoforms; the biological 
properties of pro-BDNF suggest that increases in this isoform may be responsible for 
reduced neuronal differentiation and dendritic spines and altered synaptic connectivity. 
These notions have been previously hypothesized (Teng et al., 2005) (Koshimizu et al., 
2009): Chang and colleagues showed in vivo data demonstrating a decreased expression 
of BDNF protein in the brain of MeCP2 knockout mice. These data suggest that MeCP2 
knockout mice have a reduced neuronal activity correlated with reduced BDNF brain levels 
(Chang et al., 2006) (Calfa et al., 2011)(Moretti & Zoghbi, 2006).  
BDNF receptors analysis.  
In order to complete our analysis of alteration in BDNF signaling in the brain of En2-/- 
mice, we extended our study at BDNF receptors. An increasing number of studies have 
suggested the involvement of BDNF/TrkB in various pathological conditions. BDNF/TrkB 
dysregulation leads to cellular proliferative changes and degenerative and behavioral 
changes in the brain (Gupta et al., 2013).  
83 
 
Therefore, we decided to investigate the mRNA expression of BDNF receptors: in 
particular, we performed RT-qPCR experiments, which showed a significant 
downregulation of p75 receptor in the hippocampus and cerebral cortex of En2-/- mice, 
compared to controls. TrkB expression was unchanged, with the only exception of TrkB full 
length (TrkB.FL) isoform, which was increased in the hippocampus of En2-/- mice as 
compared to WT controls (see Results. Fig.4.18). TrkB.FL plays a more prominent role in 
increasing proximal dendritic branching, whereas truncated TrkB isoforms are involved in 
the elongation of distal dendrites (Gupta et al., 2013). Recent study demonstrated that and 
increased TrkB expression leads to impair synaptic plasticity in a mouse model of Fmr1 
(Correia et al., 2010) (Louhivuori et al., 2011)(Gupta et al., 2013). Therefore, alterations in 
TrkB signaling might contribute to an increased vulnerability to autism also in our mouse 
model. It has been demonstrated that TrkB expression changes have a role in the 
development of Rett syndrome pathology as well (Abuhatzira et al., 2007). 
As for the neurotrophin receptor, p75 promotes distinct signaling pathways in the cells; in 
most cases these pathways are opposed, but sometimes they coordinate with TrkB 
promoted pathways (Gupta et al., 2013). Previous studies demonstrated that the dose 
of Engrailed is inversely correlated to the expression level of p75 (Alavian et al., 2009). 
Therefore, observing the decrease expression of mRNA p75 level in hippocampus and 
cerebral cortex of En2-/- mice, we might hypothesize that the reduction of p75 receptor 
might be caused by the loss of En2 in our mouse model.  
 
We also investigate the expression of the high-affinity BDNF receptor, TrkB, at protein 
level using western blotting experiment. The results obtained demonstrate an up-regulation 
of TrkB receptor in the hippocampus of En2-/- mice, compared to control group. Increase 
in TrkB expression has been associated with increased seizure susceptibility and 
epileptogenesis (Weskamp & Reichardt, 1991). Indeed, increase susceptibility to seizures 
has been previously shown in En2-/- mice (Tripathi et al., 2009; Sgadò et al., 2013). 
Neurotrophin receptors may act as a point of convergence, involved in the integration of 
many environmental inputs: this can lead to alterations in neuronal circuitry and, ultimately, 
in behavior (Chao, 2003). 
Effect of BDNF on En2-/- hippocampal neurons in culture.  
Previous studies demonstrated that BDNF promotes the formation of GABAergic synapses 
in hippocampal and cortical cultures and can potentially adjust the number and strength of 
GABAergic synapses onto targeted glutamatergic cells (Huang et al., 2007). We therefore 
analyzed the effect of BDNF treatment in primary hippocampal cell culture neurons.  
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Synaptic vGAT puncta were increased in En2-/- untreated cells, with no statistically 
significant increase in En2-/- vs WT neurons treated with BDNF. We could hypothesize 
that the transcriptional factor En2 might influence the number of vGAT synaptic puncta; 
indeed, we can observe that in En2-/- neurons vGAT expression tends to increase. In 
order to investigate the effect of BDNF on glutamatergic synapse density in WT and En2-/- 
hippocampal cultures, we performed the immunostaining using vGlut2 antibody. The 
analyses revealed a significant decrease in the number of vGlut2 synaptic boutons in En2-
/- cells, compared to WT. This result appears different in the cell culture treated with BDNF 
protein, in which we observed an increase of vGlut2 synaptic puncta in En2-/- treated cells. 
Observing this data, it is possible to hypothesize that the treatment with BDNF protein in 
cell culture neurons might leads to a complete rescue of vGlut2 synaptic puncta in En2-/- 
treated cells, reaching the WT untreated cells expression in our mouse model.  
5.5 Conclusions and future perspectives 
In this study, we showed marked defects in forebrain GABAergic interneurons in En2-/- 
mice. Interneuron loss was accompanied by defects of synaptic connectivity (i.e. dendritic 
spines and synaptic puncta), which might depend on marked deficits of BDNF expression 
detected in the En2-/- forebrain. Future studies will be aimed at investigating the causal 
relationship between BDNF deficits and interneuron loss in the En2-/- forebrain. 
Specifically, we will try to determine whether transgenic overexpression of BDNF in the 
forebrain is able to rescue GABAergic interneuron defects in En2-/- mice. To this purpose, 
the generation of WT and En2-/- mice overexpressing BDNF is currently ongoing in our 
laboratory. 
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APPENDIX 
Published Papers containing results present in this Thesis: 
1) Loss of GABAergic neurons in the hippocampus and cerebral cortex of 
Engrailed-2 null mutant mice: Implications for autism spectrum disorders.  
Sgadò P, Genovesi S*, Kalinovsky A*, Zunino G*, Macchi F, Allegra M, Murenu E, 
Provenzano G, Tripathi P.P, Casarosa S, Joyner A.L, Bozzi Y.  
Experimental Neurology, 247, 496–505. doi:10.1016/j.expneurol.2013.01.021;2013. 
* equal contribution as second authors 
 
In this article my contribution has been to perform morphometric and immunohistochemical 
analyses, cell counting and RT-qPCR analyses. I performed a morphometric analysis on 
dorsal hippocampal and cerebral cortex sections stained for the pan-neuronal marker 
NeuN to carefully investigate hippocampal and cortical layer structure in WT and En2-/- 
mice. I participated to the study of the reduced expression of GABAergic marker mRNAs in 
these brain areas in adult En2-/- mice. In addition, I contributed to the experiments 
showing reduction in parvalbumin (PV), somatostatin (SOM) and neuropeptide Y (NPY) 
expressing interneurons, in the hippocampus and cerebral cortex of adult En2-/- mice. The 
images correlated to this contribution are present in this thesis (see Results): 
- Fig 4.1 Immunohistochemical data of En1/En2 protein expression in hippocampus 
and somatosensory cortex. 
- Fig 4.2 Morphometric analysis in the En2-/- somatosensory cortex.  
- Fig.4.3 Reduced number of GABAergic interneurons in the En2-/- somatosensory 
cortex 
- Fig.4.7. Morphometric analysis in the hippocampus of En2-/- mice. 
- Fig.4.8. Reduced number of GABAergic interneurons in the En2-/- hilus. 
 
2) Altered GABAergic markers, increased binocularity and reduced plasticity in the 
visual cortex of Engrailed-2 knockout mice. 
Allegra M, Genovesi S, Maggia M, Cenni MC, Zunino G, Sgadò P, Caleo M, Bozzi Y.  
Frontiers in Cellular Neuroscience, 8, 163. doi:10.3389/fncel.2014.00163; 2014. 
 
I participated to this study, performing immunostaining analyses, cell counts and qPCR, 
which revealed significant differences in SOM-, NPY-, and PV- positive cell densities 
between WT and En2-/- mice, at adult age. I also contributed to the expression profile of 
GABAergic marker protein in the visual cortex that prompted us to investigate the mRNA 
expression of GABAergic interneurons in the primary visual cortex of WT and En2-/- mice 
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in adulthood. The result obtained revealed a decrease expression in GABAergic markers, 
in detail, in SOM, NPY, vGAT mRNA levels, and also in glutamatergic marker, vGlut1, in 
En2-/- mice compared to controls.  
 
The images correlated to this contribution are present in this thesis (see Results): 
- Fig.4.4. Profile of GABAergic interneurons in visual cortex, at adult age. 
- Fig.4.5. mRNA expression of En2 and glutamatergic/GABAergic markers in the 
juvenile and adult visual cortex of WT and En2-/- mice. 
- Fig.4.6 Normal neuronal density and layering in the primary visual cortex of adult 
En2-/- mice. 
 
Other Published Papers containing results not presented in this Thesis: 
3) Transcriptome profiling in engrailed-2 mutant mice reveals common molecular 
pathways associated with autism spectrum disorders.  
Sgadò P, Provenzano G, Dassi E, Adami V, Zunino G, Genovesi S, Casarosa S, Bozzi Y. 
Molecular Autism. 19;4(1):51; 2013. 
 
I participated to this study, setting up PCR conditions for differentially expressed genes of 
interest in the En2-/- hippocampus (Fig. 5 of the published paper). 
 
4) Hippocampal dysregulation of neurofibromin-dependent pathways is associated 
with impaired spatial learning in engrailed 2 knock-out mice.  
Provenzano G, Pangrazzi L, Poli A, Pernigo M, Sgadò P, Genovesi S, Zunino G, Berardi 
N, Casarosa S, Bozzi Y. 
The Journal of Neuroscience. 1;34(40):13281-8.;2014. 
I participated to this study, setting up immunostaining conditions of En2 in the 
hippocampus (Fig. 3 of the published paper). 
 
5) Mutant mouse models of autism spectrum disorders.  
Provenzano G, Zunino G, Genovesi S, Sgadó P, Bozzi Y. 
Disease Markers. 33(5):225-39.; 2012. 
 
I participated in writing some paragraphs of this review, regarding mouse ASD models; 
part of the content of this review has been used to write the Introduction of this thesis. 
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6) Early depolarizing GABA controls critical period plasticity in the rat visual cortex 
Deidda G, Allegra M, Cerri C, Naskar S, Bony G, Zunino G, Bozzi Y, Caleo M, Cancedda L. 
Nature Neuroscience, 18(1):87-96. doi: 10.1038/nn.3890. 2015 
In addition to my thesis project, I collaborated with Laura Cancedda‘s group at the Italian 
Institute of Technology (IIT_Genova), in a project regarding the interference of depolarizing 
GABA during early postnatal development on visual cortex plasticity. Bumetanide-treated 
animals present an extension of critical period of plasticity in the visual cortex, without 
affecting the overall development of the visual system. This effect on plasticity is 
accompanied by changes in fundamental regulators of plasticity and it is rescued by 
increasing BDNF signaling during depolarizing-GABA interference. Here I describe my 
specific contribution to this publication: 
Depolarizing GABAergic signaling is fundamental for early physiological maturation of 
various brain areas (Wang & Kriegstein, 2011). Inhibitory GABAergic transmission is a 
well-known regulator of visual system development and plasticity; here we studied the role 
of depolarizing GABA in the regulation of cortical plasticity.  
In order to evaluate the perinatal interference with depolarizing GABA on the critical period 
for visual cortex plasticity, we used a classical paradigm of experience-dependent plasticity 
(i.e., a brief period of 3 days of monocular deprivation, MD) in bumetanide- and vehicle-
treated rats. During the critical period, brief MD results in a dramatic shift of ocular 
dominance (OD, assessed at the end of the MD period) of cortical neurons in favor of the 
non-deprived eye (Heimel, van Versendaal, & Levelt, 2011). We performed the MD 
experiments at P17 (opening of critical period plasticity), P26 (peak of plasticity), P35 
(closure of critical period plasticity) and P75, when animals are considered fully adult and 
do not show plasticity.  
 
I participated in the study of the GABAergic interneurons development; examining their 
laminar distribution by immunostaining for the GABA biosynthetic enzyme GAD67 in 
cortical sections from bumetanide- and vehicle treated rats at P35. Count of GAD67 cells 
were performed on 3 sections for each experimental animal. For each section, images of 
the visual cortex were acquired with a 20X objective (air, 0.5 NA) by a Zeiss AxioObserver 
z1 microscope with a motorized stage. Acquisitions were automatically performed using 
the MosaiX and Z-Stack modules of the Zeiss AxioVision software (v4.3.1). I collected five 
Z-series for each image, which were projected to two-dimensional representations. Results 
showed no significant differences in the distribution of interneurons between the two 
groups of animals, treated and vehicle. 
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Fig A1. Early GABAergic interference does not alter the overall structural development of the visual 
system: 
e) Representative images acquired from coronal sections of the visual cortex from vehicle- and 
bumetanide-treated animals at P35 labeled for GAD67. Scale bar, 100 µm. Insets: higher magnification 
images from fields as reported on the left. Arrows point to examples of GAD67-positive cells. Scale bar, 
50 µm. f) Quantification of the density of GAD67-positive cells across cortical layers revealed no 
significant differences (Two Way ANOVA on ranks, P > 0.05). The histogram depicts average ± SEM. 
Numbers in parentheses: animals processed. 
 
Brain derived neurotrophic factor (BDNF) controls the closure of the critical period in the 
visual system, influencing inhibitory circuits (Heimel et al., 2011)(Fagiolini et al.,1994). In 
this work has been investigated its expression in bumetanide- and vehicle-treated animals 
at P35, founding a significantly lower levels of BDNF in visual cortices from bumetanide-
treated animals. In order to test the hypothesis that BDNF signaling is reduced in response 
to GABAA receptor activation, we collected visual cortex samples from rat pups perinatally 
treated with bumetanide or vehicle (from P3 to P8) and systemically challenged at P8 by 
acute injection of a GABAA receptor agonist. I performed quantitative RT-PCR and we 
found a significant up-regulation of Bdnf mRNA expression in vehicle-treated animals 
injected with midazolam (Mid), in agreement with the literature. Interestingly, animals 
perinatally treated with bumetanide showed no significant upregulation of Bdnf mRNA 
expression upon midazolam treatment.  
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Figure A2. BDNF mRNA expression: 
b) BDNF mRNA expression measured at P8 in vehicle- (red) and bumetanide-treated pups (green) either 
in basal condition or after induction by i.p. injection of GABAA receptor agonist Midazolam in rat pups. 
Gapdh was used as an internal standard. Two Way ANOVA analysis of variance showed that 
bumetanide treatment blocked (post Tukey test, P = 0.004) the Midazolam-induced increase (post Tukey 
test, P = 0.003) of Bdnf mRNA expression. The histogram depicts average  SEM, whereas circles 
indicate single data points. 
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